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Abstract
Scanned ion beam therapy of lung tumors is severely limited in its clinical applicability by
intrafractional organ motion, interference effects between beam and tumor motion (interplay)
as well as interfractional anatomic changes. To compensate for dose deterioration by intrafrac-
tional motion, motion mitigation techniques, such as gating have been developed. The latter
confines the irradiation to a predetermined breathing state, usually the stable end-exhale phase.
However, optimization of the treatment parameters is needed to further improve target dose cov-
erage and normal tissue sparing.
The aim of the study presented in this dissertation was to determine treatment planning pa-
rameters that permit to recover good target coverage and homogeneity during a full course of
lung tumor treatments. For 9 lung tumor patients from MD Anderson Cancer Center (MDACC),
a total of 70 weekly time-resolved computed tomography (4DCT) datasets were available, which
depict the evolution of the patient anatomy over the several fractions of the treatment. Using
the GSI in-house treatment planning system (TPS) TRiP4D, 4D simulations were performed on
each weekly 4DCT for each patient using gating and optimization of a single treatment plan
based on a planning CT acquired prior to treatment. It was found that using a large beam spot
size, a short gating window (GW), additional margins and multiple fields permitted to obtain
the best results, yielding an average target coverage (V95) of 96.5%. Two motion mitigation
techniques, one approximating the rescanning process (multiple irradiations of the target with
a fraction of the planned dose) and one combining the latter and gating, were then compared
to gating. Both did neither show an improvement in target dose coverage nor in normal tissue
sparing. Finally, the total dose delivered to each patient in a simulation of a fractioned treat-
ment was calculated and clinical requirements in terms of target coverage and normal tissue
sparing were considered. The results showed that the total V95 obtained for the entire course
of the treatment was similar to the one obtained for the planning CT, which shows that inter-
fractional variability was successfully compensated. For 4 patients out of 9, V95 > 95% was thus
obtained for both the planning CT and the total dose target coverage. For the rest of the cohort,
a slight modification of the contours or dose reduction should permit to obtain a better clinical
treatment plan that could be delivered over the course of the treatment.
In the presented study, intrafractional motion occuring during the treatment of lung tumors
was efficiently mitigated using optimized treatment planning parameters and gating, while in-
terfractional variability showed the largest impact on dose delivery. Nevertheless, this variability
was efficiently mitigated, as shown by target dose coverage obtained at the end of the treatment
which was very close to the one obtained for the planning CT.
i

Zusammenfassung
Bei der Bestrahlung bewegter Tumoren, wie Lungentumoren, mit gescannten Ionenstrahlen
können intrafraktionelle Organbewegungen, Interferenzen zwischen Tumor- und Strahlbewe-
gung (sogenanntes Interplay) sowie interfraktionelle anatomische Variabilität zu einer klinisch
inakzeptablen Dosisverteilung führen. Beeinträchtigungen der Dosishomogenität im Zielvolu-
men durch intrafraktionelle Bewegung und Interplay können mit unterbrochener Bestrahlung
(Gating) teilweise kompensiert werden, bei der der Tumor nur während des stabilsten Teils der
Bewegung bestrahlt wird. Dennoch ist eine weitere Optimierung der Bestrahlungsparameter
notwendig, um Dosisabdeckung zu verbessern sowie Normalgewebsbelastung zu verringern.
In dieser Arbeit wurden Bestrahlungsparameter quantifiziert, um gute Dosisabdeckung des
Ziels für Lungentumor-Bestrahlungen zu erreichen. Für 9 Patienten des MD Anderson Cancer
Center standen 70 4D-Computertomographien zur Verfügung, mit denen die Entwicklung der
Anatomie über den Verlauf der Behandlung beurteilt werden konnte. Für jeden Patienten wur-
den mit dem 4D-Bestrahlungsplanungsprogramm TRiP4D der GSI 4D-Rechnungen mit Gating
und einem einzigen, vor der Bestrahlung optimierten Bestrahlungsplan durchgeführt. Rechnun-
gen, die mit einem breiten Strahlfokus, einem kurzen Gating-Fenster, zusätzlichen Sicherheits-
säumen und mehreren Bestrahlungsfeldern ausgeführt wurden, erzielten die beste Abdeckung
(V95 = 96.5%). Weiterhin wurde Gating mit zwei Techniken verglichen: die erste Technik stützt
sich auf Rescanning (mehrere Bestrahlungen des Ziels mit einem Bruchteil der Dosis) und die
zweite auf eine Rescanning/Gating Kombination. Mit diesen beiden Techniken konnten keine
besseren Ergebnisse in Bezug auf Dosisabdeckung oder Normalgewebsbelastung erreicht wor-
den. Schließlich wurde in einer Simulation eines klinischen Behandlungsschemas die Gesamtdo-
sis für jeden Patient bestimmt und klinische Grenzwerte für Dosis und Normalgewebsbelastung
einbezogen. Für alle Patienten waren die Dosisabdeckung des Planungs-CTs und der ganzen Be-
handlung ähnlich; interfraktionelle Variabilität wurde also kompensiert. Für 4 Patienten wurde
ein V95 > 95% für das Planungs-CT und die totale Behandlung erreicht. Für die anderen Pati-
enten könnten eine Änderung der Kontouren oder eine Reduzierung der Dosis einen besseren
Bestrahlungsplan erzeugen, der während der ganzen Behandlung benutzt werden könnte.
In dieser Arbeit konnten intrafraktionelle Bewegungseffekte bei der Bestrahlung von Lungen-
tumoren durch optimierte Bestrahlungsparameter und Gating weitgehend kompensiert werden,
während interfraktionelle Variationen als die größere Quelle für Dosisunsicherheiten identifi-
ziert wurden. Ähnliche Dosisabdeckungen für das statische Planungs-CT und die gesamte dyna-
mische Behandlung haben dennoch gezeigt, dass diese effizient kompensiert werden konnten.
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1 Introduction
1.1 Motivation
Cancer is defined as “a group of diseases characterized by uncontrolled growth and spread of
abnormal cells” (ACS, 2011). In 2008, more than 12.5 million new cases occurred worldwide
(see Figure 1.1). It is expected to reach more than 20 million in 2030 due to population growth
and aging. Cancer is, behind heart diseases, the second most leading cause of death worldwide
with about 7.5 million of deaths in 2004, representing 12.6% of the total number of deaths.
In the developed countries it is the leading cause of death with more than 2 million deaths,
representing more than 26% of the total number of deaths.
Different types of cancer do not have the same incidence and death rates. Figure 1.2 shows an
estimated distribution of the different types of cancer worldwide in 2008 in terms of new cases
and deaths. In men, lung and bronchus are the most affected organs with more than 1 million
new cases and about 1 million already known cases leading to death. In women, breast cancer
is the most frequently occurring disease with more than 1.3 million new cases. While new lung
and bronchus cancer are only the fourth most frequently occurring type of cancer way behind
breast cancer, it is the second most deadly cancer with more than four hundred thousand deaths
each year, only a few thousand less than breast cancer.
However, the rate of death caused by cancer from the years before 1990 is currently slowing
down in the USA (Siegel et al., 2014) and it is estimated that more than 1.3 million deaths have
been averted in this country since the nineties. Nowadays, due to better prevention and more
effective treatments, the probability to die from cancer has been reduced to around 20-25% in
the developed countries (IAEA, 2008).
Worldwide, it is also estimated that 45% of all cancer patients can be cured. Among those
45%, 23% undergo radiotherapy alone or in combination with surgery or chemotherapy-
immunotherapy (IAEA, 2008; PTCOG). Radiotherapy being involved in half of the cured pa-
tient’s treatments shows that this is a commonly used and effective technique to successfully
treat cancer.
1
Figure 1.1.: Estimated number of new cases of cancer worldwide. Figure from ACS (2011).
Figure 1.2.: Estimated new cancer cases and deaths worldwide in 2008. Figure from ACS (2011).
Now, clinical studies have shown that the physical and biological properties of ion therapy can
allow obtaining better dose delivery conformity and tumor control rates as well as limited toxic-
ity, for instance in the case of tumors located near critical structures which require precise dose
delivery (Schulz-Ertner et al., 2007; Tsujii et al., 2004). Nowadays, further investigation is still
2 1. Introduction
carried out to obtain more clinical data (Durante and Loeffler, 2010). In particle therapy, pencil
beam scanning (Haberer et al., 1993), which is likely to become the most used beam delivery
technique in the future, has been developed but can currently only be used to its full potential
for static tumors such as head and neck tumors. At the moment, treatment of moving targets,
such as lung or liver tumors, with this beam delivery technique is limited by dose degradation
caused by interference effects between the scanned beam and the tumor motion on a short scale
of seconds to minutes, called interplay effects. On a longer time scale of hours to days, the treat-
ment is affected by organ motion such as bowel movement or tumor shrinkage, which can cause
changes in motion patterns and baselines (Britton et al., 2007; Sonke et al., 2008). Mitigation
techniques have been developed in order to limit the effects of organ motion on dose delivery.
Some, for instance, allow better compensation for the interplay effects previously mentioned
while others are not applicable yet, due to computational or imaging constraints.
Treatment of lung tumors using carbon ion therapy has already been studied in clinical studies
(Miyamoto et al., 2003, 2007). These studies showed promising results in terms of local tumor
control and survival, especially for older patients with complications and small sized tumors.
Also, a common practice in radiotherapy is to compute one treatment plan for the entire course
of the treatment or for a couple of weeks before it might be adapted. Following this practice,
the simulation studies presented in this dissertation aimed at obtaining satisfactory results in
terms of target dose coverage and sparing of normal tissue, using optimized treatment planning
parameters previously isolated.
1.2 Purpose of this work
As previously described, this study aimed at testing the impact of treatment planning param-
eters on dose delivery to the tumor and the organs at risk (OARs) over the entire course of a
treatment. Obtained dose distributions were evaluated using dose coverage (ICRU, 2007) and
normal tissue constraints (Grimm et al., 2011). Three main studies were carried out, all using a
single treatment plan optimized prior to treatment for each patient and applying it in successive
weekly dose calculations:
1. Firstly, using gating as motion mitigation method, the effect on dose delivery of four treat-
ment planning parameters was investigated, so that they could be optimized to obtain
conformal dose coverage of the tumor. Their effect on irradiation of surrounding organs
was also studied.
2. Secondly, using the parameters yielding the best results in the first part, results obtained
using gating and two other motion mitigation techniques, called perfect rescanning (PRSC)
and perfect regating (PRGT), were compared in order to see if target dose coverage, as well
as normal tissue sparing, could be further improved.
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3. Finally, the use of a possible replanning factor based on inter-weekly beam range changes
as well as robust field angles were investigated. Using the results of these two studies, the
optimized parameters found in the first part and the best technique found in the second
part, the simulation of clinical patient treatments was performed. This study aimed at
investigating the efficiency of the optimized parameters in a single-plan-based scanned
carbon ion beam treatment, by applying clinically used fractionation schemes and organ
dose limits and by analyzing the obtained total target dose coverage and OAR exposure.
4 1. Introduction
2 Research background & fundamentals
2.1 Particle therapy
This chapter introduces the important aspects of particle therapy, such as its biological and
physical implications. It also depicts its evolution, starting with its historical background and
finishing with its use in the treatment of moving tumors using techniques available nowadays.
2.1.1 Historical background
In January 1896, barely one month after Wilhelm Conrad Röntgen announced his discovery
of the X-rays and demonstrated one of its properties by producing the first radiograph, the first
medical use of this “new kind of ray” was reported. It had helped locating a piece of a knife in
the backbone of a drunken sailor, who was paralyzed until the fragment was removed. Shortly
after, the Austrian surgeon Leopold Freund presented the first therapy trial, he had been irradi-
ating a hairy mole on the forearm of a patient, which had disappeared (Hall and Garcia, 2011;
Kraft, 2000). Then, Antoine-Henri Becquerel described a skin erythema and its ulceration after
leaving a radium container in his pocket and Pierre Curie noticed the same effect while repeat-
ing the experiment (Hall and Garcia, 2011). This was the starting point of the study of ionizing
radiations on living things.
For a long time, radiation therapy development remained empirical. But it still followed two
main tendencies: increasing the biological effectiveness of the radiation and achieving more
conformal dose delivery to the target (Kraft, 2000). That is why, replacing X-ray tubes used at
the beginning, gamma ray based treatments were developed to reduce the dose to the tissue in
front of the target, followed by ions to increase the biological effectiveness.
The first time ions were proposed to be used as treatments for medical problems was in 1946
by Wilson (1946). His idea originated from the increasing energy of the new accelerators to
be built, resulting in higher range in tissue allowing thus reaching deeper seated regions. He
emphasized quite well the main qualities of such particles and the advantage they represent in
comparison with photons. This will be described later in this chapter.
However, although cancer treatment can benefit a lot from this technique, many uncertain-
ties are still present which have to be dealt with like relative biological effectiveness (RBE),
which is nowadays determined using different methods from one continent to another (IAEA,
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2008), for different tissue or cell types (Kase et al., 2008), intrafractional motion of moving tu-
mors (Shirato et al., 2004; Bert and Durante, 2011) and its mitigation (Rietzel and Bert, 2010;
Bert and Durante, 2011), interfractional anatomy changes or patient misalignments (Bert and
Durante, 2011), interplay effects (Bert et al., 2008), effects of inhomogeneities on the Bragg
peak (Sawakuchi et al., 2008), risks of secondary cancer (Kraft and Kraft, 2009) or organ at
risk (OAR) dose limit values used nowadays, which have been presented for instance by Grimm
et al. (2011) and Benedict et al. (2010) but which may not be “the maximal attainable safe dose”
and are “mostly unvalidated”. Jäkel et al. (2008) also published an interesting point of view
regarding the future of heavy ion therapy and the issues to be faced, in which he concluded that
heavy ion therapy still has to prove its safety and efficiency regarding some of the uncertainties
described above as well as its cost effectiveness compared to photon radiotherapy.
Despite the uncertainties listed above, proton and heavy ion therapy treatments have been
proven to be successful with many advantages such as better local control rates (Tsujii et al.,
2007; Tsujii and Kamada, 2012). Also, the number of hadron therapy centers has not stopped
increasing since the first facility in Berkeley in 1954. Nowadays, about 50 centers are in opera-
tion and more than 30 are under construction or at the planning stage (PTCOG). Besides, since
1954, more than one hundred thousand patients have been treated with protons and, since
1994 in Japan, 1997 in Germany and more recently in China and in Italy, more than ten thou-
sand with carbons ions (Jermann, 2014). Previously mentioned advantages and specificities of
particle therapy will be presented in the next sections.
2.1.2 Physical properties
The base of proton and heavy ion therapy is its favorable depth-dose profile which is natu-
rally adapted to the situation (Chu et al., 1993; Kraft, 2007; Schardt et al., 2010). Figure 2.1
shows the advantage of charged particles. The right graph of 2.1 shows the absorbed dose in
a certain depth of water for photons and ions (depth-dose-distribution). While photons have
their maximum a little below the surface (green and black curves in the right graph of figure
2.1), ions (red curves) show a sharp peak at a certain depth determined by their energy (Bragg
peak). This makes particle irradiation very interesting in the case of tumor treatment because
deep-seated tumors can be treated with high precision while sparing normal tissue.
Absorbed dose is the mean energy dE deposited by ionizing radiation in mass element m. The
unit is the Gray [Gy].
D =
dE
dm
; [D] = 1Gy = 1
J
kg
(2.1)
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Figure 2.1.: Schematic illustration of the Bragg curve (left, from Chu et al. (1993)) and compar-
ison of different depth-dose profiles (right, from Schardt et al. (2010)): the Bragg
peak is a characteristic of protons and heavier ions and can be shifted by changing
the kinetic energy of the particles.
It can be calculated using equation 2.2 where F is the fluence, ρ the mass density and dE/dx
the energy loss of the particles per unit path length.
D [Gy] = 1.6× 10−9 × dE
dx

keV
µm

× F cm−2× 1
ρ

cm3
g

(2.2)
The energy-loss rate dE/dx is then obtained by the Bethe-Bloch formula 2.3 which describes
the slowing-down process of the particles (Bethe, 1930; Bloch, 1933b,a; Fano, 1963).
dE
dx
=
4pie4ZtZ
2
p
mec2β2

ln
2mec
2β2
〈I〉 − ln
 
1− β2− β2 − C
Zt
− δ
2

(2.3)
Here Zp and Zt are the nuclear charges of the projectile and target, me and e are the mass and
charge of the electron, β = v/c (v being the velocity of the particle and c the speed of light),
〈I〉 is the mean ionization energy of the target. C/Zt is the shell correction term which takes
into account orbital velocities of the target electrons at low particle energies (Ziegler, 1999) and
δ/2 is the density-effect correction term valid for high energy particles (PDG, 2010).
Figure 2.2 shows that energy loss is mainly due to inelastic electronic scattering and that it
increases with decreasing particle energy, due to the 1/β2 dependence, up to a maximum. While
the projectile charge is equal to the atomic charge number Zp at high velocities, recombination
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processes and ionization result in a decreasing mean charge state at lower velocities causing
the inelastic electronic energy loss to drop again for lower particle energies. Thus Zp has to be
replaced by Ze f f using the following equation from Barkas (1963):
Ze f f = Zp

1− exp

−125βZ− 23p

(2.4)
Figure 2.2.: Specific energy loss dE/dx of 12C ions and protons in water from Schardt et al.
(2010).
Figure 2.2 also shows that nuclear elastic reactions become the main contribution to energy
loss when ions reach the low energies (less than 10 keV) at the end of the range. Moreover, for
both protons and heavier ions, it is possible to shift the Bragg peak and to adjust its position
by changing the kinetic energy of the incident particles (the two red curves on figure 2.1).
However, three important differences between protons and heavier ions can be isolated, heavy
ions exhibit:
• a narrower Bragg peak: range straggling is present with both protons and heavy ions in
the limit of a large number of interactions. This is directly related to energy-loss strag-
gling (Bohr, 1940; Ahlen, 1980) which follows a Gaussian distribution. The ratio of the
straggling width σR and mean range R is given by equation 2.5:
σR
R
=
1p
M
f

E
Mc2

(2.5)
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where f is a slowly varying function related to the absorber and E and M are the particle
energy and mass. In spite of this ratio being nearly constant, values for protons and heavier
ions differ due to the 1/
p
M term, meaning it is much smaller for heavy ions than for
protons. There is for instance a factor 3.5 between protons and 12C ions (Schardt et al.,
2010).
• a characteristic dose tail (see figure 2.3): this is due to nuclear fragmentation. This process
plays a significant role in absorbed dose in the case of ions heavier than protons and
consists for most of it in the peripheral collision of a projectile with the target nuclei (Kraft,
2000; Schardt et al., 2010). It can result in the complete disintegration of both elements or
partial fragmentation and generally involves two steps: first nucleons are abraded in the
contact zone and then the formed projectile emits nucleons or clusters to deexcite. Studies
like Goldhaber and Heckman (1978), Hüfner (1985) and Lynch (1987) have permitted to
isolate some effects of fragmentation:
1. primary beam particles are lost and new lower-Z fragments are created, this effect
increases with penetration depth,
2. fragments are moving with roughly the same velocity as the primary particles, have
longer ranges and cause the dose tail after the Bragg peak visible on Figure 2.3,
3. angular distributions of fragments are larger than the one of the primary ions, but still
mainly forward directed.
• a much smaller lateral beam spread at high depth (see figure 2.4): for low energy protons,
scattering occuring in the nozzle mainly determines the width of the beam while for more
energetic ones, scattering occuring in the water absorber dominates. This is mainly due to
Coulomb scattering of the projectiles (Kraft, 2000) which was described theoretically by
(Molière, 1948) and confirmed experimentally by Gottschalk et al. (1993) by measuring
proton scattering. Carbon ions do not show such a large effect and a much smaller spread
can be observed. For instance protons having a range R = 15.6 cm will show a angular
spread which is 3 times larger than for 12C ions at the same range (Schardt et al., 2010).
Hence, two effects have to be considered during treatment:
1. scattering before entering the patient caused by materials such as beam monitors or
beam shaping devices. This is usually predominant at low energies and mostly for
protons and can have significant effects on a scanned pencil beam,
2. scattering in the patient body which dominates at higher energies. Once again 12C
ions are less affected by this effect but it is large enough that it needs to be incorpo-
rated into patient treatment planning.
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Figure 2.3.: Bragg peaks of protons and 12C ions having the same range in water from Schardt
et al. (2010): the tail of the Bragg peak for ions is clearly visible. Besides, the peak of
ions is narrower than the one of protons.
Figure 2.4.: Beam spread for 12C ions and protons from Schardt et al. (2010): at high depth, the
beam spread of the protons is much more important.
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2.1.3 Biological properties
In addition to the many specificities described in the previous part, heavy ions and protons
possess a larger biological effectiveness in comparison to particles showing a low linear energy
transfer (LET) such as X-ray photons. Equation 2.3 shows the quadratic dependence of LET
(through stopping power) on the projectile charge, which leads to high values in the case of
heavier ions. It means more DNA damage on the ion tracks, especially at the end of the range,
and the heavier the ion the more important the damage as displayed on Figure 2.5.
Besides, low energetic ions present in the region of the tumor being more likely to ionize
compared to high velocity ones in the entrance channel, the biological effect is thus larger in
the target than in the preceding tissue. Also, as displayed on figure 2.5, using 12C ions permit to
produce many more electrons compared to protons, which causes more DNA damage and thus
again a larger biological effect. That is why the concept of relative biological effectiveness (RBE)
has been developed. It can be applied between two different kinds of radiation (here a reference
type of radiation compared to ions, the reference being in general X-rays, γ-rays or neutrons)
and is defined as follows: it is the ratio of the dose of a reference radiation over the dose of
ion irradiation necessary to obtain the same biological effect (isoeffect) (Schardt et al., 2010)
(equation 2.6).
RBEiso =
Dre f
Dion
(2.6)
Even though equation 2.6 looks simple, the RBE varies a lot depending on the dose (Figure
2.6) (Weyrather et al., 1999; Furusawa et al., 2000), the particle type and the energy (Belli
et al., 1998; Scholz, 2003), the biological effect level (Figure 2.6) and the considered tissue
(Weyrather et al., 1999). All these dependences were confirmed by in vivo animal studies such
as Leith et al. (1982), Zacharias et al. (1997) and Ando et al. (1998). The concept of RBE is
important because it can establish a link between ions and photons.
This link permits to see that ions have a larger biological effect than photons. Figure 2.5 shows
the ionization processes responsible for radial dose distribution for protons and 12C ions and
which comprise two main successive steps:
1. first, electrons are emitted after the interaction of the incident ion with an atom or a
molecule following inelastic coulomb interactions,
2. then, those electrons are scattered multiple times due to elastic interactions with the sur-
rounding tissue or transfer their energy to the medium by the means of ionization or
excitation.
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Besides, in Monte Carlo simulations, analytical models and experimental studies a symmetric
radial dose distribution following a 1/r2 dependence (r being the increasing distance) has been
found (Chatterjee and Schaefer, 1976; Katz and Cucinotta, 1999; Paretzke, 1986; Krämer, 1995;
Varma et al., 1977). Those ionizations and their distribution show that, compared to photons
and for the same average macroscopic dose, ions cause more dense and complex damage at the
microscopic level (Scholz, 2003), leading to a much higher probability of cell killing and making
radiation damage of ions more efficient than that of photons (Nikjoo et al., 1999).
Figure 2.5.: Monte Carlo simulation of paths of emitted electrons with different energies created
by protons and 12C ions at 0.2, 1 and 10 MeV/u in water. Size comparison with a
DNA molecule is displayed. Figure courtesy of M. Krämer.
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Figure 2.6.: Example of a cell survival curve and its use to determine RBE at 10% and 1% survival
levels. Figure from Schardt et al. (2010).
Cell survival curves are a good method to calculate the RBE for a given cell line. Those curves
generally follow the linear-quadratic (LQ) model (Hall and Garcia, 2011) given by equation 2.7:
S (D) = exp
 −αD− βD2 (2.7)
where S is the cell survival, D the absorbed dose and α and β parameters obtained experi-
mentally. The shoulder of the cell survival curve (Figure 2.6) is determined by the ratio α/β
which is often used in radiotherapy (Fowler, 2003). However other models exist, using the LQ
model on one part of the curve and adding correction terms on the remaining part, such as
the linear-quadractic linear (LQ-L) model (Astrahan, 2008; Scholz et al., 1997), the modified
linear-quadratic (MLQ) model (Guerrero and Li, 2004) or the universal survival curve (USC)
model (Park et al., 2008).
Besides, while a single value of RBE of 1.1 (Paganetti et al., 2002) is generally used for pro-
tons, there are several ways of calculating the RBE for heavier ions (Schardt et al., 2010; IAEA,
2008). In Japan, a passive shaping beam system has been designed (Kanai et al., 1997; Ka-
gawa et al., 2002) and is used for treatment. Based on experience from neutron therapy, it was
demonstrated by in vivo cell and mouse-skin reaction experiments that neutrons and 12C ions
show the same RBE for a LET of 80 keV/µm. By finding the neutron-equivalent position in a 6
cm 12C (290 MeV/u) spread-out Bragg peak (SOBP) corresponding to a clinical RBE of 3, it was
then possible to obtain the RBE in the middle of the SOBP, which was 2.38 (Kanai et al., 1999).
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In general, values between 2.1 and 2.8 were found.
It works quite differently in GSI because, due to the beam delivery system called raster scan-
ning (Haberer et al., 1993), the RBE needs to be calculated for each position in the treatment
field to calculate the effect of the photon-equivalent dose. This is performed using the local
effect model (LEM) (Scholz and Kraft, 1994, 1996). Using tables containing α values for ions
and for many energies, (Scholz et al., 1997) developed a method to quickly calculate the asso-
ciated β value. Using these values as inputs for the LQ-L model (Krämer et al., 2000; Krämer
and Scholz, 2000), it is then possible to compute the RBE for any desired biological effect if the
photon data is available. Depending on a lot of parameters, as described previously, RBE values
can vary a lot.
2.1.4 Beam delivery techniques
Shortly mentioned above, there are several ways to deliver the beam to the tumor region with,
as main requirements, accuracy and homogeneity. The two major strategies are referred to as
passive and active beam delivery (Chu et al., 1993; Schardt et al., 2010).
2.1.4.1 Passive beam delivery
In the case of passive systems (like the fully passive system of figure 2.7), several elements
are used to shape the beam delivered by the accelerator so that areas within the contours of the
tumors are treated.
Figure 2.7.: Passive beam delivery system, from Schardt et al. (2010).
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First the beam is broadened using a scattering device, then the range-modulator spreads out
the monoenergetic Bragg peak so that the range of tumors in depth which can be treated is
adjustable, next the range-shifter allows to adapt the position of the Bragg peak. Finally the
collimator, which can be a multi-leaf collimator (MLC), cuts out the field area (the contour of
the tumor) and the compensator (Figure 2.8) is used to adapt the distal depth according to
the tumor shape and the tissue composition (Figure 2.8). Those two last elements are patient
specific and must always both (when the collimator is not a MLC) be precisely fabricated. Work
on design of many of these elements was done at the Harvard Cyclotron Laboratory (Koehler
et al., 1975, 1977; Gottschalk and Wagner, 1989).
Figure 2.8.: Double wedge system used as a range shifter (left) and collimator-compensator sys-
tems (right) used to shape the beam. Figure from Chu et al. (1993).
The principle of the range shifter (like the double wedge system on figure 2.8) is to increase or
decrease the depth of the material (for instance PMMA) so that the Bragg peak can be shifted.
The energy loss is indeed linked to the depth of material (equation 2.3) so that the thicker
the range shifter, the larger the shift. It can either be used with a single SOBP which covers
the whole length of the tumor, but it has obvious limitations like dose delivery in the tissue
surrounding the tumor (see figure 2.9.a), or be dynamically used (associated with a dynamic
collimator) for the stacked irradiation technique which uses several smaller SOBPs to cover the
tumor length (see figure 2.9.b), thus reducing the dose in the tissue the vicinity of the tumor
(Chu et al., 1993; Schardt et al., 2010). However, cases presented in figure 2.8 and 2.9 are
simple shaped tumors, and facing complex shaped ones could yield negative effects. More dose
could for instance be delivered in the normal tissue for case (a) of figure 2.9 or, as it is not
possible to vary dose level within one layer in case (b) of figure 2.9, dose inhomogeneities could
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appear in some areas of the tumor due to the irradiation of previous layers (like for a “H” shaped
tumor).
Figure 2.9.: Fixed configuration of the range shifter and the collimator (a), dynamic configura-
tion of the range shifter and the collimator (b). Figure from Chu et al. (1993).
2.1.4.2 Active beam delivery
Scanning techniques permit to reduce those drawbacks. As well as for passive beam delivery
techniques, several different methods exist. In the case of the raster scanning technique, the
volume is first divided in voxels.
Figure 2.10.: GSI raster scanning system. Figure from Kraft (2007).
Then, for each position of the beam in the tumor (called raster point), a certain particle
number is calculated and each one of these points contribute to several voxels of the target.
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Finally a “pencil-like” beam is directed to each raster point as long as the particle number is not
reached. Lateral scanning is done using fast magnets to irradiate the volume of the tumor. The
adaptation of the position of the Bragg peak can be done by changing the beam energy either
by using the accelerator or by using a range shifter like for the passive beam delivery stacked
irradiation technique. Spot scanning, whose difference compared to raster scanning is that the
beam is switched off between two raster points and which was first developed in Japan (Kanai
et al., 1983) but then mostly used in PSI in Switzerland (Pedroni et al., 1995) is the other main
technique used nowadays.
Figure 2.10 shows how raster scanning was implemented at GSI (Haberer et al., 1993) and
then used at HIT in Heidelberg. Many advantages of scanning techniques can be pointed out,
such as no patient specific hardware (like collimator or compensator used in the passive beam
delivery techniques), a dose which can be varied from one voxel to another, allowing to com-
pensate for the irradiation of the previous voxels, and a drastically reduced amount of material
in the path of the beam upstream to the patient (no beam shaping needed), reducing particle
loss and production of secondary particles like neutrons.
However it does require high precision and robustness of the accelerator and the control and
safety systems in order to obtain stable and reproducible the beam positions. Today the trend
is to replace passive beam delivery systems with active ones in the existing centers or to always
use active techniques for new centers in construction.
Moreover, with the development of new gantries capable of rotating the beam direction
around the patient like at HIT, it is possible to combine the precision of scanning techniques
with the ability to deliver dose from any direction, resulting into a system which is able to target
the tumor with high accuracy.
2.2 Tumor motion and its mitigation
Physical and biological properties of hadron therapy have been introduced in the previous sec-
tions. They showed that the precision of this technique allows conformal irradiation of a tumor
by delivering high dose to a desired volume while sparing the normal tissue in the vicinity, due
to the sharp dose fall-off obtained with protons or heavy ions. Now, the conformity mentioned
above can be severely deteriorated when the tumor is located in areas of the body being subject
to motion, such as the lungs during respiration or any other organ drifting between two fractions
of the treatment. Indeed, due to very high range and tissue density sensitivity, treating moving
tumors with ion therapy can lead to high dose deposition in the surrounding tissue. That may
result in toxicity and late effects such as necrosis (Cox et al., 1995). Thus, it is mandatory to
understand the origin and impact of the different types of organ motion and anatomy changes
and how they can be compensated. This section will introduce these three aspects.
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2.2.1 Organ motion and anatomy changes
(Langen and Jones, 2001) use three categories to classify the different types of motion or
changes which can occur during a treatment:
Patient motion can appear between two fractions or during the treatment as well as during
imaging. Immobilization techniques and devices have been developed to suppress or di-
minish this type of motion, which are nowadays clinically used.
Interfractional motion happens between two fractions of the treatment and can be seen on
successive 4DCTs. It generally consists of organ shifts, tissue drifts and tumor shrinkage.
Interfractional anatomic changes were described by (McClelland et al., 2011) who ob-
served baseline shifts of several points in the lung or by Mori et al. (2009) who observed
lung density changes and lung tumor shrinkage.
Intrafractional motion happens during beam delivery. It is mainly caused by breathing and
heartbeat and shows different amplitudes from one patient to the other depending on the
location of the tumor. Shirato et al. (2004) stated that respiratory organ motion is indeed
the largest intrafractional motion which can be observed. Several studies have quantified
this motion and observed that its main component is in general along the superior-inferior
(SI) direction (Seppenwoolde et al., 2002; Britton et al., 2007; Liu et al., 2007). The
anteroposterior (AP) and left-right (LR) components generally have smaller amplitude.
In this work, patient motion and interfractional motion are grouped together under the name
of interfractional changes or interfractional variability and both intrafractional motion and in-
terfractional changes are addressed. They can indeed cause undesired and large negative effects
on dose delivery.
2.2.2 Consequences of tumor motion
In the case of scanned ion beam therapy, the three types of organ motion described above
cannot only be considered as simple geometrical motions. Geometrically, it can be compared to
photon beam therapy because, due to motion, the tumor goes out of the field repeatedly so that
no conformal dose delivery can be obtained (Bortfeld et al., 2004). But using scanned ion beam
therapy adds radiological effects which are larger than for conventional photon beam therapy.
Both interfractional changes and intrafractional motion can result in a negative impact on dose
delivery with under- and overdose in the target as well as in the OAR.
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2.2.2.1 Radiological path length
Interfractional changes and intrafractional motion can both affect the radiological path length.
Intrafractional motion is responsible for tumor motion during the treatment, as described in the
previous subsection. Figure 2.11 displays the effects of respiratory organ motion along the
radiological depth. Due to anatomic changes between the inhale and exhale phases, the latter
is severely affected by changes in tissue density on the path of the beam (Bert and Durante,
2011). The same principle applies for interfractional changes, for which even larger anatomical
differences can be observed compared to intrafractional motion (Nøttrup et al., 2007). Organ
shifts or tissue drifts, as well as patient misalignment, sometimes lead to large geometrical
changes, causing huge changes in radiological depth due to, for instance, higher tissue density
possibly coming from the presence of bony material instead of muscle in the path of the beam.
(Lomax, 2008b) also studied interfield motion (which can occur between two dose deliveries
relative to two fields in a multiple fields treatment) and reported severe underdose in the tumor
as a consequence of a simple 5 mm shift in the dose distribution. Moreover, both interfractional
changes and intrafractional motion can be encountered at the same time and their effects are
then added.
Figure 2.11.: Amplitude of the radiological pathlength changes from the inhale phase to the
exhale phase. A moving tumor does not only imply geometrical changes but also
radiological pathlength changes due to differences in tissue density. Figure from
Bert and Durante (2011).
2.2.2.2 Interplay effects
In the case of scanned ion beam therapy, another effect has to be taken into account due to
a double dynamic system composed of a moving tumor and a moving scanned pencil beam.
Interferences of scanned beams and intrafractional organ motion, called interplay effects, can
lead to severe inhomogeneity and largely deteriorated dose delivery (Lambert et al., 2005;
Groezinger et al., 2006; Bert et al., 2008), as illustrated on figure 2.12, and can thus not be
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neglected. They strongly depend on the amplitude of the tumor motion, the relative direction
of beam motion and target motion (Phillips et al., 1992) and multiple other factors. It has
been demonstrated that irradiating the target multiple times (rescanning, see next section)
permits to reduce these effects. Regarding the scanning direction, using beam scanning planes
perpendicular to the tumor motion direction yields worse results compared to parallel scanning
(see figure 2.12). Also, using additional margins has been proven to be ineffective regarding
those interference effects (Phillips et al., 1992; Lambert et al., 2005; Groezinger et al., 2006;
Bert et al., 2008).
Thus, in order to be able to efficiently treat tumors affected by the different types of motion
and their consequences on dose delivery, different strategies had to be developed, which will be
described in the next section.
Figure 2.12.: Illustration of the impact of interplay effects on radiographic films. The scanning
direction is horizontal. (a) represents the static case and (b) and (c) represents the
dose delivery to radiographic films using a vertical and an horizontal target motion,
respectively. Figure from Bert et al. (2008).
2.2.3 Tumor motion mitigation
2.2.3.1 Margins
A first solution to reduce the effects of intrafractional motion or interfractional variability is
to use different types of margins to extend the irradiated region. To do so, different additional
volumetric layers exist. Figure 2.13 illustrates them according to their definition in ICRU (1993,
1999), which are given here:
Gross tumor volume GTV: “The GTV is the gross palpable or visible/demonstrable extent and lo-
cation of malignant growth.”
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Clinical target volume CTV: “The CTV is a tissue volume that contains a demonstrable GTV and/or
subclinical microscopic malignant disease, which has to be eliminated. This volume thus has
to be treated adequately in order to achieve the aim of therapy, cure or palliation.”
Internal target volume ITV: “This is the margin that must be added to the CTV to compensate
for expected physiological movements and variations in size, shape, and position of the CTV
during therapy.”
Planning target volume PTV: “The PTV is a geometrical concept, and it is defined to select an
appropriate beam size and beam arrangements, taking into consideration the net effect of
all the possible geometrical variations, in order to ensure that the prescribed dose is actually
absorbed in the CTV.”
Organ at risk OAR: “Organs at risk are normal tissues whose radiation sensitivity may signifi-
cantly influence treatment planning and/or prescribed dose.”
However, extending the irradiated volume results in more dose delivered to the normal tissue.
This can become a serious problem when the motion of the target is large. To avoid that, some
special beam delivery techniques exist which are presented below.
Figure 2.13.: The initial target and successive additional volumetric layers. The visible part of
the tumor is contained in the GTV, the CTV takes possibly non-visible tumor spread
into account, the ITV is composed of several motion state-specific CTVs and the
PTV adds another volumetric extension.
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2.2.3.2 Gating
Gating permits to mitigate intrafractional motion by only irradiating the target during a por-
tion of a motion signal. The latter can either be obtained directly using fluoroscopic imaging,
which yields the motion of the tumor itself (Shirato et al., 2000; Berbeco et al., 2004), or in-
directly using external surrogates such as the ANZAI AZ-773V system (ANZAI MEDICAL CO.,
LTD) or laser triangulation systems (Minohara et al., 2000), which yield a signal correlated to
the tumor motion. Thus, the tumor is only irradiated when the motion signal enters a previously
chosen interval, called gating window (GW), and, in the case of a synchrotron, when the ac-
celerator is ready to deliver the beam. As a consequence, a significantly smaller residual tumor
motion has to be dealt with (see figure 2.14).
Figure 2.14.: Principle of the gating technique. The beam can be delivered when the gating sig-
nal is triggered, meaning when the motion signal enters the gating window (GW),
but only if the pulsed beam of the synchrotron is available. This permits to obtain
a significantly smaller residual motion, whose amplitude depends on the choice of
the GW.
This technique has been developed about 25 years ago (Ohara et al., 1989) and is used nowa-
days in many centers in the world (Minohara et al., 2000; Iwata et al., 2010; Lu et al., 2007),
mostly for tumor sites affected by respiratory motion such as the lungs (Iwata et al., 2010;
Miyamoto et al., 2003; Nihei et al., 2006) or the liver (Chiba et al., 2005). As shown on figure
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2.14, the end-exhale phase of the motion signal is often chosen as GW, because it is the phase
for which this signal is the most stable (Balter et al., 1998; Ritchie et al., 1994).
Other studies using conventional radiotherapy have tested the feasibility of replacing the mo-
tion signal by the actual motion of the tumor obtained using megavoltage (MV) imaging, allow-
ing then to measure if the tumor motion is inside or outside the GW (Berbeco et al., 2005b,a;
Cui et al., 2007b,a, 2008; Tai et al., 2010). The advantage is that no additional dose is deliv-
ered to the patient, but MV-fluoroscopy offers very bad contrast compared to kilovoltage (kV)
fluoroscopy, making the extraction of the tumor trajectory complex.
Now, one of the big disadvantages of gating is the increased duration of the treatment de-
livery, due to the fact that the target is only irradiated during part of the breathing cycle and,
the shorter the GW, the longer the treatment delivery. Also, because of interplay effects due
to residual tumor motion within the gating window, gating has not been used in centers using
scanned ion beams and may require some more investigation in order to obtain conformal dose
delivery (Bert et al., 2009).
2.2.3.3 Rescanning
Phillips et al. (1992) showed that irradiating the target multiple times with a proportionally
reduced dose results in improved dose delivery. It is thus the principle of rescanning, which
consists in irradiating the PTV multiple times. Similarly to gating, it permits to mitigate the
effects of intrafractional tumor motion and obtain a homogeneous dose in the CTV. However,
even though only a fraction of the dose is delivered in each rescan, the entire PTV is each time
irradiated, which means surrounding tissue is also irradiated. Rescanning also allows mitiga-
tion of interplay effects by averaging them over several rescans. Specific characteristics can be
found in Rietzel and Bert (2010). Zenklusen et al. (2010) also presents different rescanning
configurations which could potentially be used in the future with the new gantry at PSI. The
two most studied rescanning methods are slice-by-slice and volumetric rescanning (Bert and
Durante, 2011). The first one aims at delivering the prescribed number of rescans to each slice
successively while the second one delivers the rescans to the entire volume n times. Some other
hybrid configurations exist, combing rescanning with gating, which will be described below.
Finally, the number of fields, which is itself a kind of rescanning as the target is irradiated mul-
tiple times from different directions, has also been proven to improve dose homogeneity (Knopf
et al., 2011).
It has been mentioned above that gating is sensitive to residual motion interplay effects.
To limit their impact, some studies have been carried out, which combine gating and rescan-
ning. Two methods, phase-control rescanning (PCR) (Furukawa et al., 2007, 2010) combined
with gating at NIRS and breath-sampling rescanning (BSR) (Seco et al., 2009) at PSI, were
developed. The original PCR technique did not include gating, but combining gating and res-
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canning permits indeed to cumulate capabilities of intrafractional motion mitigation of the two
techniques while rescanning allows compensating for interplay effects.
2.2.3.4 Tracking
Tracking is a technique that allows potentially the best dose conformity. It was first proposed
by Keall et al. (2001) for IMRT. It was shown in the study of Brown et al. (2007) that only 3
to 5 mm geometric margins around the GTV are needed and consitute the tracked irradiated
volume (called PTV in their study). However, it requires precise motion monitoring and very
fast computations in order to adapt the beam delivery laterally and, in the case of ion beam
therapy and due radiological pathlength changes, in depth. Tracking is already used clinically
in the Cyberknife Synchrony system (Accuray Inc., Sunnyvale, CA, USA) which uses a linear
accelerator mounted to a robotic arm capable of compensating for intrafractional tumor motion
(Brown et al., 2007; Kilby et al., 2010).
Tracking for a scanned ion beam system has been developed and implemented at GSI with
initial studies performed by Groezinger et al. (2004, 2008). Lateral compensation was done
using the raster scanning system and range compensation was performed using linear motor-
driven double-wedge system (Weber et al., 2000). It has been implemented in the GSI treatment
planning system (TPS) (Bert et al., 2007, 2010; Saito et al., 2009) and showed precision in terms
of technical aspects as well as dosimetry. However, its clinical use is nowadays limited by the
fact it is no online technique, meaning the 4D tracking treatment plan is generated using 4DCT
imaging done before the treatment itself, meaning interfractional changes could occur in the
meantime.
Some other techniques are being developed. Fassi et al. (2014) described a method relying
on 4DCT imaging as well, but using an external surface surrogate to deform the 4DCT in order
to adapt to the anatomy of the concerned treatment fraction and to generate a new breathing
motion model.
This part showed the different types of motion which can appear during the treatment of
tumors located in anatomic sites affected by organ motion. The consequences of those different
motions as well as the methods used to mitigate them were then described. Some of them
are already implemented in 4D treatment planning systems (4DTPSs) and used clinically. The
next section will expose how moving tumors can be treated using a 4DTPS and what treatment
schemes and organ dose limits are available.
2.3 Treatment of moving tumors
Because some tumors can be affected by organ motion, it was necessary to develop 4DTPSs
capable of yielding treatment plans taking this motion into account. It required 4D anatomic
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information in order to calculate 4D-dose delivery and to implement the motion mitigation
methods described above. The whole process aims at obtaining conformal dose delivery during
each fraction of the treatment and limited irradiation of the surrounding tissue.
2.3.1 Time resolved computed tomography
Using anatomical data from the patient is mandatory to generate radio- or hadrontherapy
treatment plans. X-rays have been used for medical imaging since the very end of the 19th
century with the first radiograph. Since that time, machines and methods using X-rays have
evolved a lot. Computed tomography CT is today the most commonly used method to obtain
patient anatomical information in order to perform both radio- and hadrontherapy. It consists
in one or two X-ray tubes rotating very fast around the patient. A detector ring (or more than
one ring) detects the irradiation transmitted through the patient. The x-rays are attenuated by
Compton or photoelectric effects when going through the patient (Kraft, 2000). One (or more,
depending on the number of rings) axial slice of the patient is then reconstructed. The patient
is moved for the acquisition of all needed slices and, thus, the 3D volume.
The obtained 3D dataset is composed of voxels whose values (CT numbers) are called
Hounsfield units HU which represent the attenuation coefficients relative to water. While
the lower values (-1000) represent air or vacuum, the higher values (2000) are reached for
bony structures and 0 is used for water. Those units are obtained using the following equation:
HU (~x) = 1000× µ (~x)−µW
µW
(2.8)
where µ(~x) and µW are the X-ray absorption coefficients in tissue at location ~x and in water,
respectively (Schardt et al., 2010). However, in order to properly calculate dose deposition
during the treatment using CT, range values for each voxel have to be known. Water-equivalent
path length WEPL values give the range of particles such as protons or 12C ions in water and
are linked to CT numbers. The first approximation of the relationship between CT numbers
and WEPL values for 12C ions was given by Minohara et al. (1993). One of the most recent
calibrations is displayed on figure 2.15.
The basic CT technique has also been modified to be faster such as cone-beam computed
tomography (CBCT) (Sonke et al., 2005) or used in temporal CT series, called time-resolved
computed tomography (4DCT), to depict different phases of the motion of moving tumors.
4DCT is the most important 4-dimensional volumetric imaging technique, because 4D-treatment
planning used for the treatment of moving tumors relies on CT data for dose calculations. It
has been developed about 10 years ago (Ford et al., 2003; Keall, 2004; Rietzel et al., 2005)
and permits, using techniques such as deformable registration, to map an anatomic point from
one motion phase to any another. Several deformable registration algorithms exist such as
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those presented by Brock et al. (2006) and Rietzel and Chen (2006). Brock (2010) published a
large comparison of the different algorithms used in several institution and concluded that the
accuracy of deformable registration is generally similar to the voxel size. Combined to 4DCT,
this tool is very useful for 4D-treatment planning, which is explained in the next section.
Figure 2.15.: Relationship between CT numbers in Hounsfield units HU and water-equivalent
path length (WEPL) values for 12C ions. Figure from Rietzel et al. (2007).
2.3.2 4D treatment planning
At GSI, an in-house 4DTPS is available, TRiP4D (Richter, 2012), based on TRiP98 (Krämer
et al., 2000) and modified to be capable of generating 4D treatment plans for moving tumors.
The different steps necessary to obtain a 4D treatment plan and the 4D dose delivery are de-
scribed below.
First, it is necessary to have 4D data, which is provided by 4DCT. In addition, the tumor and
the organs have to be contoured on at least one motion phase. Then, using the deformation
maps obtained from deformable image registration, it is possible to propagate those contours to
all motion states composing the 4DCT. Then, the target has to be defined. In the case of moving
tumors, the target is usually composed of several tumor motion states, forming the previously
described ITV. The concept of ITV has however been improved from its simple geometrical de-
sign to a volume taking WEPLs into account, as shown by Graeff et al. (2012) and Knopf et al.
(2013).
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Because no 4D-optimization process has been developed for particle therapy yet, a static treat-
ment plan is first optimized on the ITV and is then used to generate a 4D-treatment plan. The
latter is obtained from the static treatment plan by using the temporally correlated information
from a motion surrogate signal and the time structure of the beam delivery, the beam delivery
sequence and sorting all raster points with respect to the motion phases they were delivered
in Richter (2012). Treatment plan and beam delivery can in principle incorporate any motion
mitigation method which has been described in the previous section. Accelerator specifications
and parameters included in the beam delivery sequence are mandatory to correcly reproduce
the double dynamic nature of the system composed of the scanned beam and the moving tumor
and thus to model interplay effects. Depending on the chosen motion mitigation technique, the
dose corresponding to each raster point of the static treatment plan is distributed differently
among the motion states of the 4D treatment plan. For instance, in the case of gating, the dose
of each static raster point is distributed among the states composing the gating window.
Finally, the 4D biological or physical dose delivery can be simulated. 4D dose calculation has
also originally been implemented in the GSI TPS by Gemmel et al. (2011) and accumulates the
dose for each voxel over all motion states by using the same deformation maps used for contour
propagation. This permits to accumulate the dose delivered in each motion state in one dose
distribution matching the anatomy of one motion phase (called reference motion state). This
reference motion state and the obtained dose distribution can then be overlaid to determine the
quality of the 4D dose delivery.
2.3.3 Treatment schemes and constraints
Treatment plan have to be carefully generated regarding the organ at risks (OARs) in the
vicinity of the tumor. Due to organ motion and the physical characteristics of ions, treatment of
moving tumors can cause large dose delivery errors with high dose delivered to the surrounding
tissue. The previously described motion mitigation techniques permit to reduce these errors
more or less, depending on which technique is chosen. For instance, gating theoretically allows
less OAR irradiation than rescanning, due to a smaller irradiated volume. Now, to improve dose
delivery in the target, some treatment planning parameters have been investigated, which can
allow obtaining better conformity, such as the beam focus width (Bert et al., 2009; Steidl, 2011;
Richter, 2012) or the number of rescans and the number of fields (Knopf et al., 2011). Satisfac-
tory dose delivery, which is generally obtained for target coverage (V95) within a 95%/107% of
the planned dose interval as recommended in ICRU (2007), was obtained in those studies using
optimized parameters. But, if the latters permit to obtain better target dose coverage, they may
result in more OAR irradiation and, because the previously mentioned studies focused on the
target, no analysis was done concerning the dose delivered in critical structures outside of it.
In clinical studies and depending on the institute, different OAR constraints have indeed been
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set and used for IMRT treatments. Grimm et al. (2011) published a large overview in which
dose/volume limits as well as maximal point doses are listed. As described by Benedict et al.
(2010), those limits are however mostly unvalidated and based on clinical experience, but they
still give an indication of how much dose is tolerated for each organ.
Also depending on the institute, beam delivery and motion mitigation techniques, as well as
treatment schemes, vary. While Miyamoto et al. (2003, 2007) presented 9 and 18 fractions-
based treatments using gating and passive beam delivery with different investigated doses per
fraction for each fractionation scheme, some protocols including both chemotherapy and proton
therapy can be found on PTCOG. So, nowadays, both OAR constraints and treatment schemes
are institute-specific.
2.4 Summary
This chapter presented an overview of ion beam therapy. Physical and biological advantages
of the technique have been pointed out, showing the benefits of using ions compared to pho-
tons. It has also been shown that different beam delivery techniques were developed and used,
even though active beam delivery tends to become the most used beam deliver technique in
the future in particle therapy. Also, potential problems occurring in the case of moving tumors
have been discussed, as well as the different methods to mitigate them. Finally, the creation
of a 4D-treatment plan using the GSI 4DTPS has been described. It has also be shown that
treatment characteristics are institute-specific, depending on which beam delivery system and
motion mitigation techniques are available as well as different clinician experience.
Now, one aspect of treatment is used in each institute, which is to generate a single treatment
plan for the entire course of the treatment or, at least, for several fractions before it might be
adapted. Using one treatment plan as well, this study aimed at investigating which parame-
ters could be optimized to obtain both satisfactory dose delivery in the tumor and OAR sparing
(chapter 3) and which mitigation technique can realistically be used (chapter 4). Two brief
studies were also performed to determine if a replanning factor and field angles robust to inter-
fractional variability can be isolated (chapter 5). Using the obtained results, a final treatment
planning study was carried out to investigate the total dose delivered to the tumor and the OAR
over the entire course of the treatment (chapter 5).
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3 Treatment parameters optimization to
compensate for interfractional anatomy
variability and intrafractional tumor
motion
3.1 Introduction
Treating moving targets such as non-small cell lung cancer (NSCLC) tumors using photon ra-
diation therapy has been investigated (Korreman, 2012) and is being clinically used nowadays
combined to real time tracking (Brown et al., 2007; Kilby et al., 2010). However, using heavy
ion scanned beam therapy has shown many advantages compared to conventional radiotherapy
(Amaldi and Kraft, 2005; Tsujii et al., 2008) by reducing the number of fields which have to be
used as well as the dose delivered to the organs at risk (OARs) in the vicinity of the tumor. It
also demands high precision and accuracy when applied to moving tumors because of the pos-
sible dose delivery error induced by range shifts themselves due to both intrafractional motion
and interfractional anatomic changes and patient misalignments (Mori et al., 2008; Bert and
Durante, 2011).
This is why several motion mitigation techniques such as gating, rescanning or tracking have
been developed and are still under development (Knopf et al., 2010). Gating (Ohara et al.,
1989; Minohara et al., 2000) is a technique which consists in turning the beam on when the
moving tumor reaches a precise motion state, in general at the end of exhalation while the
tumor is the most stable. It has shown great potential and has thus been successfully used in
Japan combined to passive ion beam delivery (Tsujii et al., 2004; Iwata et al., 2010; Tsujii and
Kamada, 2012). Active scanned beam delivery introduces interplay effects (Bert et al., 2008)
and even though tumor motion mitigation techniques are used, these effects can lead to non-
conformal dose delivery. In order to address specifically this problem, 4D treatment planning
systems (4DTPSs) have been implemented (Bert and Rietzel, 2007; Richter et al., 2013) and
permit to simulate treatment of moving targets using gating while also taking interplay effects
into account.
Nonetheless, treatment parameters still have to be optimized to maximize motion mitigation
obtained using gating. Several studies have been performed to determine the influence of dif-
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ferent parameters on the dose delivery: Bert et al. (2009) proposed to increase pencil beam
overlap to mitigate interplay effects as well as Steidl (2011) and Richter (2012) whose studies
displayed the effects of different lateral grid spacing, iso-energy slice distance, focus size and
Bragg peak width. In a combination gating and rescanning, Furukawa et al. (2007) proposed a
method called phase-controlled rescanning, aiming at compensating further the residual tumor
motion within the gating window. Rescanning was used as mitigation technique by Knopf et al.
(2011) and the impact of the entry channel was also investigated through different field scenar-
ios. Target definition including tumor motion, size and position (ICRU, 1999) as well as range
adapted margins were discussed (Koto et al., 2004; Engelsman et al., 2006; Bert and Rietzel,
2007; Knopf et al., 2013) and implemented (Graeff et al., 2012).
However, those studies concentrated on intrafractional motion compensation, meaning that
the possible anatomic variability between the time of the treatment planning CT and treatment
or also between fractions was not taken into account. Simulations were in general restricted to
a single 4DCT taken for treatment planning.
The purpose of this study was to investigate which parameters could be isolated and opti-
mized in order to compensate correctly for both intrafractional tumor motion and interfrac-
tional anatomic changes and/or patient misalignments. To this end, in a cohort of patients with
a time series of 4DCTs and for different combinations of treatment and/or beam parameters,
one gating plan was optimized using the first weekly 4DCT of each patient and was forward
calculated on the successive 4DCTs of the weeks following treatment planning. Results were
then compared to determine the best configuration.
3.2 Materials and methods
3.2.1 Patient cohort
Data from 9 NSCLC lung tumor patients from MD Anderson Cancer Center (MDACC) (Britton
et al., 2007) were used to perform this study, reaching a total of 70 weekly 4DCTs datasets.
Each 4DCT was composed of 10 3DCTs representing 10 different tumor motion phases over the
breathing cycle. End-exhale, referred to as state n°5, was set as the reference state.
Number of weeks, motion amplitude, angles for single field and multiple fields calculations,
clinical target volume (CTV) volumes with and without additional margins are listed in table
3.1. Number of weekly 4DCTs per patient varies between 6 and 10, those were used as fraction
numbers. Most of the patients have an average tumor motion below 5 mm and only one patient
shows a tumor motion above 20 mm (Patient 9).
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3.2.2 Treatment planning
3.2.2.1 Image Registration
Rigid registration of reference phases of each subsequent CT was performed to mimic patient
setup and alignment. A short study has also been done to investigate if rigid registration was
more precise using only bony anatomy rather than soft tissue. Comparison of the two methods
has demonstrated that bony anatomy based rigid registration lead to a significant improvement
in only one case over the 15 weeks of 2 patients studied (see appendix A). It was thus decided to
use only soft tissue rigid registration to align CTs. Then non-rigid registration was used between
each 4DCT motion phase using Plastimatch (Shackleford et al., 2010).
Table 3.1.: Description of the 9 NSCLC Patients from MDACC (see figure 3.1 for field angles illus-
tration): patient number, number of weeks available, mean motion amplitude and
range, field angle for single field calculations (SFUD), field angles for multiple fields
calculations (SFUD1, 2 & 3), volume of the CTV (CTV) and volumes of the extended
target: 3mm isotropic (I3), 3mm+3% range (R3) and combination of both (I3+R3).
Angles [degree] Volumes [cc]
Pat. Weeks Motion [mm] SFUD SFUD1 SFUD2 SFUD3 CTV I3 R3 I3+R3
1 8 3.4 240 180 225 270 236 322 406 518
2 6 8.6 0 0 315 270 574 718 891 1057
3 9 10.1 0 270 315 0 161 213 335 409
4 8 3.3 225 180 225 270 676 819 925 1089
5 10 4.1 0 0 315 270 372 472 648 791
6 8 1.8 0 0 315 270 705 828 935 1072
7 7 1.6 180 180 225 270 124 172 253 322
8 8 4 180 180 225 270 45 65 102 133
9 6 23.5 180 180 225 270 125 164 203 250
For each patient, contours were provided by physicians of MDACC for the first weekly 4DCT,
including the gross tumor volume (GTV), the clinical target volume (CTV) and the planning
target volume (PTV) for the tumor, and the OARs esophagus, heart and spinal cord. For patients
1 to 8 PTVs were generated for conventional radiotherapy treatment, but for patient 9 it had
to be created using TRiP by adding 3 mm isotropic margins to the CTV. Those PTV contours
were only used in the later automatic definition of lung contours. Files containing vector fields
(between the first week and the following ones) obtained using deformable registration were
3.2. Materials and methods 31
then used to propagate the previously mentioned contours from the reference phase of the
first weekly CT to the reference phases of the following ones (Richter et al., 2013). Finally,
vector field files yielded by deformable registration applied on the 10 states of each weekly
4DCT permitted to propagate the contours from the reference state to the 9 other motion states.
Concerning the lungs, a contour extraction algorithm based first on Hounsfield units related
thresholding was implemented and used to obtain separately the left and right lungs contours
for the reference phase of each 4DCT (see appendix B for details).
Figure 3.1.: Field angles used (see Table 3.1)
3.2.2.2 Optimization and 4D calculations
In this chapter, the technique used to mitigate motion was gating. All gating plans were sim-
ulated using the GSI treatment planning system TRiP4D (Richter et al., 2013), based on TRiP98
and modified to allow 4D-dose calculations.
For each patient, plans were initially optimized to the ITV of the first week’s CT using one
unique planned dose of 8.1 Gy(RBE). Motion related geometrical and range changes were con-
sidered according to Graeff et al. (2012). The generated raster scanning plan was then used for
all 4D calculations of the first week itself and the followings ones as well, meaning that only
one plan was used per patient and that there was no replanning before simulating the weeks
following the first optimized week. In each case, the ITV was built using a combination of five
CTVs (Graeff et al., 2012) from five different motion phases representing 25% of the amplitude
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(see figure 3.2). The motion surrogate was defined according to Lujan et al. (1999), i.e. a sine
square, as displayed on figure 3.3, with a unique period of 3.6 seconds. Only one starting phase
(0 degree) was studied because, due to gating, beam delivery for different starting phases is
quickly synchronized after the first few spills of the synchrotron accelerator, thus calculations
yield very similar results for different starting phases.
Figure 3.2.: Creation of a range-corrected internal target volume (ITV), first (in the case of this
study) combination of five motion phases associated geometrically composes the
geometric ITV which is then corrected for density changes (like bones or air of the
lung) in the path of the beam. This correction leads to the final range-corrected ITV.
Figure 3.3.: Motion surrogate and gating windows (see appendix C).
As other fixed treatment parameters, the distance between each raster position was set to 2
mm on each iso-energy slice (IES) and the distance between two IESs was set to 3 mm water-
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equivalent using a ripple-filter (RiFi) of 3 mm (Weber and Kraft, 1999). The contour extension
value (see appendix D), which defines the part of the lateral dose fall of which is taken into
account in the simulations, was set to 0.35.
3.2.2.3 Investigated parameters
The impact of different treatment plan parameters on the dose delivery was investigated
using the field angles listed in table 3.1. First, using one single field (see column “SFUD” of
table 3.1 and figure 3.1) and ITV margins only, variations in focus size and length of the gating
window (GW) were performed. Three GWs: 11.9%, 30% and 50% of the amplitude (see figure
3.3) and three beam foci: 6mm, 10mm and 15mm (FWHM) were chosen as varying parameters.
Two configurations in particular were compared:
- LFSG: large focus (15mm) and short GW (11.9%),
- SFLG: small focus (6mm) and long GW (50%).
As a second part, using the same single field angles, additional margins added in the optimized
plans were also investigated as another solution to recover good target coverage. Three different
cases were studied: 3mm isotropic margins (geometrical, referred to as I3), 3mm+3% range
margins (water equivalent, referred to as R3) and combination of both (referred to as I3+R3,
see figure 3.4). Resulting dose deliveries were compared to the results obtained using ITV only.
Combinations of GWs and foci (same 3 foci and 3 GWs than in the previous paragraph) were
again investigated in each case to observe the impact of additional margins on the range.
Figure 3.4.: Different margins cases used in the second part of the study. From the left to the
right, configurations displayed are referred to as ITV, I3, R3 and I3+R3.
Finally, still using the 9 possible GW/focus combinations, the number of fields was varied from
1 to 3 (see table 3.1 for field angle values, columns “SFUD1” to “SFUD3” and figure 3.1) using
only ITV margins first and then using the additional PTV margins which had been determined
to yield the best results in the second section of this chapter, resulting in the following cases:
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- SFITV: single field to ITV only,
- SFPTV: single field to the isotropic/range margins (same as I3+R3),
- 2FITV: ITV only but with 2 fields,
- 2FPTV: same margins as SFPTV but with 2 fields,
- 3FITV: ITV only but with 3 fields,
- 3FPTV: same margins as SFPTV but with 3 fields.
3.2.3 Data analysis
In each case, the dose distribution of each week was obtained by accumulating the dose
delivered to each motion state on the reference phase of the 4DCTs using state-to-state non-
rigid vector fields. And to estimate the impact of each previously described parameter and
configuration on the dose delivery, four different indexes were used for the tumor itself:
- Target coverage, V95: volume of the target to which 95% of the planned dose is delivered,
representing the quality of target dose coverage, unit is percentage of volume,
- Overdose, V107: volume of the target to which 107% of the planned dose is delivered, rep-
resenting the volume affected by overdose in the tumor, unit is also percentage of volume,
- Homogeneity, D5 − D95: the lower, the better (D5 and D95 being the dose delivered to 5%
and 95% of the target in the dose volume histogram (DVH), respectively),
- Conformity number (CN) (van’t Riet et al., 1997): allowing a quantification of the high dose
regions inside and outside the tumor (the higher, the better) and defined by:
CN =
V95%,CTV
VCTV
× V95%
VCTV
(3.1)
where V95%,CTV is the V95 value defined above, VCTV the volume of the CTV and V95% the
total volume which receives at least 95% of the dose.
The combination of those four indices permits to determinate precisely the quality of the dose
delivery in the tumor but two additional indexes were needed to specifically estimate the impact
of the different parameters and configurations on the dose delivered to the OARs:
- 20% volume dose, V20: allowing knowing the volume which receives 20% of the dose, unit
is percentage of volume,
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- Maximal point dose (MXD): maximal voxel dose received in the tumor, unit is Gy(RBE).
The main focus of this study is the impact of treatment plan parameters on dose delivery. All
dose calculations were computed for the weekly simulations but not for the cumulated total
treatment regime. Therefore, OAR limit dose values from the literature were not taken into
account in this chapter, but are used only a general indicator of plan quality. In chapter 5 the
total dose delivery over the entire course of the treatment is computed and also clinical dose
limits are considered. This chapter aims at determining clearly the effect of the investigated
parameters on the decreased quality of the dose delivery due to both interfractional anatomy
changes and intrafractional tumor motion.
In each case, a Wilcoxon signed-rank test (W ) was performed using a level of significance of
0.05 to estimate the difference between two sets of datapoints. In the case of samples containing
more than 10 values, the p-value (p) was computed using the obtained z-score (z).
3.3 Results
All simulations were performed on the weekly 4DCTs with a planned dose of 8.1 Gy(RBE). In
all following figures the average value (marker), the median value (horizontal bar in the box),
the 25th and 75th percentile and the total range of all values are given. In some cases, different
types of simulations were studied and referred to as:
- 3D0 simulations: planned, static dose simulations using the first weekly CT (week 0 in ref-
erence phase),
- 4D0 simulations: 4D dose simulations using the first weekly 4DCT (week 0) and the same
plan than 3D0 simulations, which contains the effects of intrafractional motion only,
- 4DN simulations: 4D dose simulations using all following weekly 4DCTs (weeks 1 to 5-9)
and the same plan than 3D0 simulations, which contains the effects of both intrafractional
motion and interfractional patient anatomic changes.
3.3.1 Beam focus and gating window
First the impact of the focus size and the length of the GW was investigated. Figure 3.5
shows V95, V107, homogeneity (D5 − D95) and conformity number (CN) for different GW/focus
combinations, for all patients.
3D simulations show conformal results no matter which combination is used, even though
slightly better results were obtained using the largest focus (W >Wcri t ical). High average V95 of
about 99%, average CN between 0.64 and 0.72, average homogeneities of about 5% and V107
almost equal to 0% are obtained in each case.
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Looking at the 4D0 results permits to see the effect of intrafractional tumor motion on the tar-
get coverage: V95 ranges increase drastically while V95 average values decrease, overdose (V107)
goes from almost 0% to more than 14% for some cases and homogeneity is also degraded. Be-
sides, an influence of focus and GW on V95, V107 and homogeneity can already be pointed out
(W >Wcri t ical): using a large focus and a short GW (configuration LFSG) increases the average
V95 up to 99.3%, compared to the 86.8% obtained with the smallest focus and the longest GW
(configuration SFLG) and V107 and homogeneity go back to 0% and around 5%, respectively.
CN, however, shows no significant (W < Wcri t ical) change between the two configurations but
decreases slightly compared to static calculations.
4DN results of the following weeks permit to investigate the effect of intrafractional motion
as well but also interfractional changes. The latter, coupled to the first one, degrades V95, ho-
mogeneity and CN compared to the 4D0 simulations. And, as well as for the latter, an impact
of focus and GW on V95, V107, homogeneity and CN is present. Again, using configuration LFSG
permits to obtain higher V95 (p < 0.05), illustrated by an average of 90.9% compared to 77.7%
obtained with configuration SFLG, lower V107 (p < 0.05) with an average falling down to 0%
and better homogeneity (p < 0.05), its mean value being reduced to 10.7% compared to 24.5%.
Although figure 3.5 shows similar ranges and average values for CN, using configuration LFSG
permits to improve the results slightly but with enough significance (p < 0.05).
Figure 3.6 shows the impact of configurations LFSG and SFLG, respectively the best and worst
combinations previously found in terms of tumor dose delivery quality, on the dose delivered
to five organs at risk: the esophagus, the heart, the spinal cord, the ipsilateral lung and the
contralateral lung. Bars are quite large for all organs for V20 as well as for MXD except for the
MXD in the ipsilateral lung: this is due to the fact tumors were not located at the same place
for all patients and that different field angles were used. However, the ipsilateral lung was al-
ways irradiated by definition, which is why the MXD values are in the same order of magnitude.
Looking at each combination separately, 3D0 and 4D0 yield approximately the same results in
terms of average values and ranges. 4DN calculations show similar average values but with
V20 and MXD maximal values which are often higher, such as the spinal cord for which V20 and
MXD maximal values reach 30% and 9.7 Gy(RBE), respectively, compared to the 3.7 to 7.9%
and the 4.6 to 6.9 Gy(RBE) obtained for static and 4D0 calculations, or the heart for which V20
maximal values reach about 13.3% to 22% compared to the 5 to 12.8% obtained for static and
4D0 calculations.
Now, looking at the differences between the best (LFSG) and the worst (SFLG) combinations
permits to isolate some effects caused by these two configurations. In the case of 4DN simula-
tions, for which both interfractional anatomic changes and intrafractional motion are present,
V20 values are only slightly increasing, but with enough significance (p < 0.05), when the best
configuration (LFSG) is used compared to the results obtained with the worst one (SFLG). In
the case of the spinal cord, MXD also increases slightly (p < 0.05) for configuration A but aver-
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Figure 3.5.: Impact of the focus and the GW on V95, V107, homogeneity and CN. Each 3D0 and
4D0 bar is composed of 9 points and each 4DN bar of 61 points (homogeneity bars
for 4DN calculations are in fact composed of 59 points due to two weeks for which
more than 5% of the volume of the tumor was not irradiated, making it impossible
to calculate the D95 value, and thus the homogeneity).
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Figure 3.6.: Impact of the best and worst focus/GW on the dose delivered to the OARs. Results
for five organs at risk are displayed: the esophagus, the heart, the spinal cord and
the ipsilateral and contralateral lungs. Each 3D0 and 4D0 bar is composed of 9 points
and each 4DN bar of 61 points.
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age values remains similar at about 2.5 Gy(RBE). For the other organs, MXD decreases slightly
(p < 0.05) when the best combination is used and average values are again very similar at
around 7 Gy(RBE) for the esophagus, 6 Gy(RBE) for the heart and the contralateral lung and 9
Gy(RBE) for the ipsilateral lung.
Dose distributions of simulations done using the two combinations of the smallest focus and
the longest GW and the largest focus and the shortest GW are displayed for the 7th weekly CT
of patient 3 on figures 3.11.a-c and 3.11.d-f, respectively.
3.3.2 Margins
After the focus and the GW, different types of additional margins were investigated and com-
pared to the ITV only as presented in the previous section. Figure 3.7 shows the impact on
V95, V107, homogeneity and CN for ITV only (ITV), ITV + 3mm isotropic margins (I3), ITV +
3%+3mm range margins (R3) and a combination of both margins (I3+R3), respectively.
3D0 simulations yield similar results in terms of average V95 at around 99%, V107 at 0% and
homogeneity at 5%. ITV (ITV) and additional isotropic margins (I3) also show similar CN with
mean values of about 0.68, but the minimal value is lower in the second case (0.53 compared
to 0.45). Using range margins (R3) and the isotropic/range margins combination (I3+R3) re-
duces CN (p < 0.05), illustrated by average values falling down to 0.51 and 0.53, respectively.
4D0 results show similar V107 and homogeneity distributions in each case, very slightly di-
minishing (less than 1% and about 1.5%, respectively, p < 0.05) when additional margins are
added. V95 gradually increases when additional margins are used (p < 0.05), the I3+R3 case
yielding the best results with an average value of 96.6% even though there no significant differ-
ence with the R3 case (z < zcri t ical , mean value of 96.3% for the R3 case). The R3 and I3+R3
cases allow obtaining better V95 than the I3 case (p < 0.05, mean value of 95.9% for the I3
case), the latter yielding itself better V95 than the ITV case (p < 0.05, mean value of 94.7%).
CN is degraded when additional margins are used (p < 0.05), illustrated by mean values going
from 0.64 in the ITV case to 0.53, to 0.5 and to 0.42 for I3, R3 and I3+R3, respectively.
Finally, results obtained from 4DN simulations follow the same behavior than 4D0 results but
have larger distributions (except for V107). V95 increases with additional margins (p < 0.05),
the best target coverage being obtained with the I3+R3 case. Also range margins yield better
results than isotropic margins (p < 0.05) in terms of V95, homogeneity and V107. The latter, as
well as for 4D0 results, decreases very slightly but with enough significance (p < 0.05). Homo-
geneity is also better when additional margins are used (p < 0.05), with average values going
from 16.6% in the ITV case to 11.8% in the I3 case, to 10.3% in the R3 case and down to 8.9%
in the combined isotropic/range margins case. CN follows the same trend than for 3D0 and 4D0
simulations (p < 0.05), with decreasing mean values of 0.5 in the ITV case, 0.46 when isotropic
margins are used, 0.45 for range margins and 0.39 for the combination of both.
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Figure 3.7.: Impact of additional margins on V95, V107, homogeneity and CN: ITV (ITV margins
only), I3 (3mm isotropic margins), R3 (3mm+3% range margins) and i3+R3 (3mm
isotropic + 3mm+3% range margins). Each 3D0 bar is composed of results obtained
using all 9 patients and 3 foci, representing 27 points, and each 4D0 and 4DN bar are
composed of results obtained using all 9 patients, 3 foci and 3 GWs, representing 81
and 549 points, respectively (homogeneity 4DN bars are in fact composed of only
531 points due to the same reason described in the legend of figure 3.5).
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Figure 3.8.: Impact of additional margins on the dose delivered to the organs at risk. Results are
displayed for five organs at risk: the esophagus, the heart, the spinal cord and the
ipsilateral and contralateral lungs. Each bar is composed of results obtained from all
4D calculations (4D0 and 4DN put together) of all weeks of all patients using 3 foci
and 3 GWs, representing 630 points per bar.
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Figure 3.8 shows the impact the different margins on the dose delivered to the OARs. Looking
at V20 first, using additional margins increases gradually the irradiated volume (p < 0.05), with
mean values going from 26.8% (ITV) to 33.4% (I3+R3), from 2.9% (ITV) to 7.2% (I3+R3)
and from 3.5% (ITV) to 7.9% (I3+R3) in the case of the esophagus, the spinal cord and the
contralateral lung, respectively. For the heart and the ipsilateral lung, V20 values obtained using
range margins are slightly lower than those obtained using isotropic margins (p < 0.05). How-
ever, for those two OARs, the lowest values are still obtained using ITV margins only (p < 0.05)
with average values of 4.8% and 18.4% and the highest ones using the isotropic/range margins
combination (p < 0.05) with average values of 7.1% and 23.6%.
Now, looking at the maximal point dose, values are very similar in all margins cases for each
OAR with slight increases or decreases only. However, those are significant enough (p < 0.05)
to be pointed out. In the cases of the esophagus, the heart, the spinal cord and the contralat-
eral lung, MXD increases as additional margins are used. I3+R3 simulations yield the highest
values, followed by R3 simulations which are themselves higher than the I3 simulations. Con-
cerning the ipsilateral lung, R3 simulations yield lower MXD values than ITV, I3 and I3+R3
simulations, for which results cannot be significantly differentiated (z < zcri t ical). Moreover, for
each margins case most of the MXD values remain between 8.5 and 10 Gy(RBE).
Dose distributions (using again the 1st and the 7th weekly CTs of patient 3) using the
largest focus and the shortest GW combined to ITV margins (ITV), ITV and additional 3mm
isotropic margins (I3), ITV and additional 3mm+3% range margins (R3) and ITV and addi-
tional 3mm isotropic and 3mm+3% range margins (I3+R3) are displayed on figures 3.11.d-f,
3.11.g-i, 3.11.j-l and 3.11.m-o, respectively.
3.3.3 Number of fields
After margins, increasing the number of fields was carried out to investigate the effect on dose
delivery. Figure 3.9 shows the impact of the number of fields combined or not with margins.
3D0 simulations yield very similar results in all cases for V95 and homogeneity, even though
the best results are obtained using the 3FPTV combination (p < 0.05). V107 seems to increase
when more fields are used (p < 0.05), illustrated by mean values going from about 0% to 3.7%
and 2.2% in the ITV and the PTV cases, respectively. CN increases gradually with the number of
fields (p < 0.05) with an exception in the SFPTV case which shows higher values than 2FPTV
and 3FPTV cases (p < 0.05). Also, values obtained using PTV margins are lower (p < 0.05),
following the trend of the mean values: 0.68, 0.72, 0.73 and 0.53, 0.47, 0.49 for the SFITV,
2FITV, 3FITV and SFPTV, 2FPTV, 3FPTV, respectively.
In the case of the 4D0 calculations, V95 increases slightly using more fields (p < 0.05), as
shown by higher mean values of 97.6% and 97.4% in the 2FITV and 3FITV cases, respectively,
compared to 94.7% in the SFITV case. Using PTV margins make those values increase further
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(p < 0.05) by 1.5% to 2%. V107 and CN values follow the same trend than for 3D0 calculations
(p < 0.05), the first ones going from 1.6% to 4.1% in the ITV cases and from 0.9% to 2.4% in the
PTV cases and the second ones from 0.64 to 0.71 in the ITV cases and from 0.42 to 0.48 in the
PTV cases. Homogeneity values are similar in all cases but some significant trends (p < 0.05)
can be pointed out: 2FITV simulations yield better values than the two other ITV cases, 2FPTV
and 3FPTV simulations yield better values than SFPTV cases and each PTV simulation permits
to obtain better results than the corresponding ITV simulation.
About 4DN results and looking first at the results obtained using only ITV margins, increasing
the number of fields makes the mean V95 increase (p < 0.05), with mean values going from
85.1% with one field to 88.1% with 2 fields and to 87.3% with 3 fields. Using PTV margins
makes V95 further increase (p < 0.05), reaching a mean value of 96.9% in the 3FPTV case. ITV
margins’ V107 mean values are similar to the ones obtained using PTV margins results although
values increase slightly as more fields and margins are used (p < 0.05). Increasing the number
of fields also permits to make homogeneity decrease and CN increase (p < 0.05). Adding PTV
margins makes V107 values and CN values diminish further (p < 0.05) down to 37.4% and 0.48,
respectively, for 3FPTV, the lowest CN mean value being reached for SFPTV at 0.39.
Figure 3.10 displays V20 and the maximal point dose using the same 6 fields/margins com-
binations. Looking at ITV simulations first, it is possible to observe different behaviors for the
OARs. In the esophagus, using more fields makes V20 increase slightly (p < 0.05) with 2FTIV
simulations yielding higher V20 than 3FITV simulations while MXD is reduced (p < 0.05), 2FITV
and 3FITV yielding similar results (z < zcri t ical) lower than SFITV simulations. For the heart,
2FITV and 3FITV simulations yield lower and higher V20 than SFITV simulations, respectively
(p < 0.05), while MXD increases gradually with the number of fields (p < 0.05). V20 in the
spinal cord is higher when two fields are used compared to one and three fields calculations
(p < 0.05) while MXD is lower in the case of 3FITV simulations (p < 0.05), the two other ones
yielding similar results (z < zcri t ical). In the ipsilateral lung, using more fields also increases
gradually V20 (p < 0.05) as well as MXD which is higher in the 3FITV case (p < 0.05). Finally,
the 3FITV configuration allows lower V20 and MXD in the contralateral lung (p < 0.05).
Now, adding PTV margins has the same significant (p < 0.05) impact for each OAR on V20 as
well as on MXD. For each OAR, both of them increase slightly compared to the corresponding
ITV simulations.
Example dose distributions using week 6 of patient 3 from single field ITV simulations (SFITV)
and single field, 2 fields and 3 fields PTV simulations (SFPTV, 2FPTV and 3FPTV) can be ob-
served on figures 3.11.d-f and 3.12.a-f, respectively.
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Figure 3.9.: Impact of different numbers of fields on V95, V107, homogeneity and CN: 1, 2 and 3
fields with ITV (ITV margins only) and PTV (3mm isotropic + 3mm+3% range mar-
gins). Each 3D0 bar is composed of results obtained using all 9 patients and 3 foci,
representing 27 points, and each 4D0 and 4DN bar are composed of results obtained
using all 9 patients, 3 foci and 3 GWs, representing 81 and 549 points, respectively
(homogeneity 4DN bars are in fact composed of only 531 points due to the same
reason described in the legend of figure 3.5).
3.3. Results 45
Figure 3.10.: Impact of different numbers of fields on the dose delivered to the organs at risk.
Results are displayed for five organs at risk: the esophagus, the heart, the spinal
cord and the ipsilateral and contralateral lungs. Each bar is composed of results
obtained from all 4D calculations (4D0 and 4DN put together) of all weeks of all
patients using 3 foci and 3 GWs, representing 630 points per bar.
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Figure 3.11.: Dose distributions of patient 3 using different weekly CTs and configurations for
single field calculations. Pink contours represent the CTV. First column displays
3D0 simulations, second column 4D0 simulations and the third one 4DN simula-
tions using week 6. Cases a-c and d-f are obtained using the SFLG and the LFSG
configurations, respectively, with ITV margins only. Examples g-i, j-l and m-p are
obtained using the LFSG configuration in combination to 3mm isotropic margins,
3mm+3% range margins and the combination of both previous margins, respec-
tively. An evolution of target coverage, homogeneity, overdose and OAR dose
delivery is clearly visible. Compared to 3D cases, 4D simulations show the effects
of intrafractional motion and interplay for the simulations done using week 0 and
the effects of interfractional changes in addition for cases simulated using week
6. Using a larger focus and a shorter GW in combination to isotropic and range
margins permits to obtain better target coverage and homogeneity, no significant
overdose but OARs are more irradiated.
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Figure 3.12.: Dose distributions of patient 3 using different weekly CTs and configurations for
different numbers of field. Pink contours represent the CTV. First column displays
3D0 simulations, second column 4D0 simulations and the third one 4DN simulations
using week 6. Cases a-c, d-f and g-i are obtained using the LFSG configuration com-
bined to isotropic and range margins and one, two and three fields, respectively.
An evolution of target coverage, homogeneity, overdose and OAR dose delivery is
here again clearly visible. Compared to 3D cases, 4D simulations show the effects
of intrafractional motion and interplay for the simulations done using week 0 and
the effects of interfractional changes in addition for cases simulated using week
6. These effects are quite well mitigated here. Using a larger focus and a shorter
GW in combination to isotropic and range margins and more fields shows further
target coverage and homogeneity improvement, a little overdose near the tumor
(due to a low contour extension value) and better sparing of OARs.
3.3.4 Tumor motion and size dependence
Results concerning the impact of some parameters on the dose delivery have been presented
in the three previous sections but no distinction was done between patients. Some additional
results will be presented here which depict the influence that the size and the motion magni-
tude of the tumor can have on the quality of the treatment and how two different parameter
combinations can mitigate it.
First, the influence of the motion magnitude on V95 and homogeneity is displayed on the left
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and middle graphs of figure 3.13. The results here are that, looking at the red configuration,
small motion patients have mean V95 20% higher and homogeneity 18% better than large mo-
tion patients and that, looking at the green configuration, this influence is reduced to 3% and
2% for V95 and homogeneity, respectively.
Dependence of CN to the size is shown on the right graph. Patients with smaller tumor show
mean CN 25% and 16% lower than bigger ones using the red and green configurations, re-
spectively. The green configuration mitigates thus in average less the influence of the size on
CN.
Figure 3.13.: Influence of motion magnitude on V95 and homogeneity and tumor on CN, using
two different treatment configurations. The red configuration represents simula-
tions done using 1 field, a focus of 6 mm, a 50% GW and ITV margins only and the
green configuration 3 fields, a focus of 15 mm, a 11.9% GW and PTV margins (3mm
isotropic + 3mm+3% range margins). For the left and middle graphs, bars repre-
senting tumors whose motion is lower than 6 mm are composed of 21 and 20 points
for V95 and homogeneity (3 patients, 21 weeks), respectively, while bars represent-
ing tumors whose motion is larger than 6 mm are composed of 49 and 48 points
for V95 and homogeneity (6 patients, 49 weeks), respectively (one less point/week
for homogeneity because of the same reason described in the previous figures). In
the case of the right graph, small tumor (< 200cc) bars are composed of 30 points
(4 patients, 30 weeks) and big tumor (> 200cc) bars are composed of 40 points (5
patients, 40 weeks). See table 3.1 for more details about patients.
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3.4 Discussion
In this study, a time series of 4DCTs of lung cancer patients was investigated for inter- and
intrafractional effects of motion, anatomic changes and setup errors. Most studies of particle
therapy for moving targets focus on 4DCTs at a single time point, assuming nearly perfect
treatment conditions. In this respect, the findings of this study offer highly important, previously
unstudied information for a more clinically realistic scenario.
3.4.1 Beam focus and gating window
Results show that the larger the focus and the shorter the GW, the better are V95, V107 and
homogeneity, meaning intrafractional motion mitigation is more effective using a large focus
and a short GW, as illustrated by figure 3.11. Only the volume of the target (see table 3.1 and
figure 3.13) seems to have a direct impact on CN: CN values yielded from simulations done with
bigger targets (patients 1, 2, 4, 5 and 6) are higher than with smaller ones (patients 3, 7, 8 and
9); that can be observed on figure 3.13 (and especially for the presented cases with ITV margins
only). Thus GW and focus do not show a significant influence on CN, which does not have a
particular behavior regarding those parameters and is more patient specific: the range of the
distributions for each week of each patient is not very large, except for patient 9 (see appendix
E.1). That means that, although V95 increases using a large focus and a short GW, the total
volume to which 95% of the planned dose is delivered increases as well, meaning that OARs in
the vicinity of the tumor are irradiated. Nonetheless, the increase seems to be moderate since
CN is not heavily influenced.
In both studies by Steidl (2011) and Richter (2012), a larger focus permits to obtain better
results in terms of homogeneity and target coverage, which is in agreement with what has been
observed here. However, while a decreasing CN is obtained with increasing focus size in the
study by Steidl (2011), this behavior is not present in the study by Richter (2012) and here.
This can be explained by the fact Steidl (2011) used a different CN which integrates the dose
values obtained in all the voxels of the CTV and thus ignores the high interplay-dependency of
V95, the latter being itself the main component of the here used CN. Richter (2012) shows that
CN is decreasing with larger foci only for static cases (a behavior which can be also observed
for static cases on figure 3.5), while it is more patient specific for cases with motion and tends
to converge on values obtained with static cases. The same behavior is observed here: weekly
detailed figures of each patient from appendix E.1 show that CN is really patient and week spe-
cific, meaning that no real typical impact of focus or GW can be highlighted. As a global result,
CN is slightly higher for larger focus, but when studied separately for each patient and each
week, CN values do not show any systematic behavior.
The fact that the focus size has a much more significant influence on the results compared
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to gating window can also be noticed. This is obtained due to the size of the largest focus (15
mm) which is larger than the tumor motion for patients 1 to 8 or similar to the tumor motion
for patient 9 (see table 3.1). Hence it is much easier to cover the moving tumor with this large
focus.
Concerning the dose delivered to the OARs, it is in general not so different when the worst
(longest GW/smallest focus) and the best (shortest GW/largest focus) configurations are com-
pared (figure 3.6) in terms of V20 and MXD. OAR irradiation is also related to the patient
anatomy, the location of the tumor and the chosen field angle. Even though a slight increase of
the V20 values can be observed, results obtained using a larger focus are quite similar to those
obtained using the smallest one. Now, although V20 increases in the case of the ipsilateral lung
(which would have been expected considering the use of a larger focus and the fact the tumor is
located in this lung), this represents an increase of a volume in which only 20% of the planned
dose is delivered, meaning that, even though this low dose region is slightly larger around the
tumor, high dose regions do not follow this evolution (as shown by a stable CN).
But comparing V20 and MXD obtained from the 3D0 and 4D0 simulations to those obtained
from 4DN simulations permits to see that another factor deteriorates the precision of the beam
delivery: interfractional anatomic changes. Indeed, in some cases and due to those changes, re-
sults are unsatisfactory compared to all the other values of the other weeks of the same patient.
Those cases also show typically lower V95, lower CN and lower homogeneity and deteriorated
dose distributions (see figures 3.11.c and 3.11.f). This can be observed on figure 3.5 with the
minimal V95 values obtained from the 4DN simulations, which are really below those obtained
from 3D0 and 4D0 simulations, as well as on figure 3.6 on which V20 maximal values for the
esophagus, the heart, the spinal cord and the contralateral lung increase when simulations with
motion are done using weeks following the planning week. Dose distributions of those weeks
and overlaid CTs (concerned week and optimized week) from each patient clearly show dif-
ferent types of motion such as organ shifts, tissue drifts and patient misalignment. Overlaying
weekly CTs permits to notice that, sometimes, the shape of the entry channel of the patient
is completely different from one week to the other, resulting in density changes which lead to
range errors which themselves are responsible for a deteriorated dose delivery quality in the
target and an increased irradiation of the OARs. Registration can also be a problem but it is very
rare (see appendix A).
Dose distributions displayed on figure 3.11 can summarize what has been said before: inter-
fractional changes (very large in the case of the patient displayed on figure 3.11.c and 3.11.f but
also linked to the choice of the entry channel) between the displayed and the planning week
cause an enormous range difference, leading to large dose delivery errors. However, V95 and
homogeneity are clearly better using a large focus and a short GW (figures 3.11.d-f) as well as
V107 (less pink areas on figures 3.11.d-f compared to figures 3.11.a-c, meaning less overdose).
Besides, in this extreme case, OARs receive more dose because of interfractional changes again
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(figures 3.11.c and 3.11.f), but those are generally not so important, which means irradiation
of OARs remains similar, as shown by the average values of figure 3.6.
3.4.2 Margins
Nonetheless, to recover for the interfractional changes, the study then consisted in using addi-
tional ITV-PTV margins. In his Study, Shirato et al. (2004) concluded in 2004 that a reduction of
the margins cannot be recommended to reduce intrafractional motion. Knopf et al. (2013) and
Albertini et al. (2011), using different sorts of margins, confirmed that margins permit indeed
to compensate efficiently for tumor motion. Figure 3.7 shows improving results when the irra-
diated volume is extended. Sorted by increasing order isotropic, range and the isotropic/range
combination margins yield better results, for both 4D0 and 4DN simulations (3D0 remaining
similar except for CN): V95, homogeneity and CN are quite sensitive to additional ITV-PTV
margins. V95 and homogeneity improve indeed significantly in terms of distribution range and
mean value. And even though the effects of interfractional changes can still be observed for 4DN
simulations (low minimal V95 and high maximal homogeneity values), using a combination of
additional isotropic and range margins permits to increase the minimal V95 value of those by
20%, as well as also improving the homogeneity by 20% compared to the cases for which only
ITV margins are used. That means logically that combining those two margins to extend the
irradiated region permits to cover the possible anatomic changes from one fraction to another
better.
CN, however, reduces due to more dose delivered in the vicinity of the target volume. This can
be observed in figure 3.11.d-o: V95, V107 and homogeneity are improved but the irradiated vol-
ume outside the tumor clearly increases gradually as more additional margins are used. OARs
in the vicinity are indeed being more irradiated, as shown by the increasing V20 values of figure
3.8 However the maximal point dose remains similar or is only slightly higher, which is quite
logical considering isotropic margins only add 3 mm to the target and range margins mostly
affect the treated lung, whose MXD was already quite high.
V107 is apparently not very sensitive to margins. Figure 3.7 shows that distribution ranges
and mean values remain in the same order of magnitude and if there is a change, it is patient
specific and cannot be observed as a systematic behavior (see patient specific weekly graphs in
appendix E.1). Considering margins are only an extension of the volume, this result is fairly
expected, considering the good V107 already obtained in the previous part by just using a large
focus on tumors, whose size varies from about 50 cc to more than 700 cc.
Figures 3.11.d-f and 3.11.m-o show how margins can allow dose recovery in the tumor for
a patient with severe intra- and interfractional motion. In this case, combination of range and
isotropic margins permits to reach a mean V95 value 20% higher compared to the use of ITV
margins only. Homogeneity is also largely improved by 15% by using combined isotropic/range
52 3. Treatment parameters optimization to compensate for interfractional anatomy variability and intrafractional
tumor motion
margins. Thus, to the conclusions of Knopf et al. (2013) and Albertini et al. (2011), stating that
intrafractional motion can be mitigated by the use margins, can be added the fact that margins
also allow to compensate efficiently for dose delivery deterioration caused by interfractional
changes. However, it is also clearly visible that OARs such as the spinal cord and of course the
ipsilateral lung are more irradiated. But, again, OAR irradiation is patient, tumor location and
field specific (as shown by very large V20 distributions in the case of the esophagus for instance),
meaning choosing an appropriate entry channel is very likely to reduce the dose delivered to
the spinal cord in the example of figure 3.11.
To conclude this part about margins, the combination of isotropic and range margins showed
the best results in terms of target coverage and homogeneity, allowing further recovery of de-
teriorated dose delivery mainly due to interfractional anatomic changes. However, because of
the extended volume but also depending on the tumor location, more dose was delivered in the
OARs near the tumor.
3.4.3 Number of fields
As a possible solution to reduce the dose in the OARs and further improve dose delivery in
the target, using more fields with or without ITV-PTV margins was investigated. First, using
more fields only combined to ITV margins permits indeed to increase V95 and to obtain better
homogeneity and CN. The fact V95 is lower when three fields are used compared to cases using
only two fields can be easily explained: there is nowadays no automatic optimized method to
choose field angles due to patient specific anatomies, so they were chosen such as one field is
set in the left-right (LR) direction directly headed to the tumor, one 45° further in the direction
of the anteroposterior (AP) axis and one in the AP direction going from the chest to the back.
However, using this technique can unfortunately result in a third field going through shifted
tissue (because of interfractional changes), leading then to range errors. This is why, for the
final study of this thesis, the range changes from one week to another were studied to try to
isolate directions which could be less affected by interfractional changes. Despite this result,
even though target coverage may be deteriorated due to a questionable entry channel and the
effect of interfractional changes being clearly visible on figure 3.9 with a very large difference
in average value as well as in distribution between 4D0 and 4DN calculations, homogeneity
and CN, which are apparently less influenced by field directions, are still further improved. This
shows that choosing field directions carefully to avoid regions affected by interfractional changes
would result in good target coverage, good homogeneity and good CN. This is in agreement
with Knopf et al. (2011), who showed that better homogeneity can indeed be obtained using
multiple fields, the difference between her study and this one being that the motion mitigation
technique used in her study was rescanning.
V107 is increasing here, but it is due to the use of 0.35 as the contour extension value in
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TRiP4D (see appendix D). A value of 1.1, as recommended by Weber (1996), will be used in
the next chapter and yields much better V107 results close to 0% for three field calculations.
Due to the high number of computations and the likely minor impact on the final conclusions,
simulations were not repeated with a higher contour extension value.
Using additional margins like previously presented, meaning the combination of isotropic and
range margins, permits to improve further results. V95 average values for 4DN simulations tend
to converge to the values obtained for 4D0 simulations, showing that interfractional changes
are almost completely mitigated. Low minimal values are still present but are higher than in the
ITV cases. The same behavior can be observed for homogeneity whose mean values for 4D0 and
4DN simulations are almost identical. In this case maximal homogeneity values obtained using
ITV-PTV margins are also reduced compared to the corresponding ITV case. CN is however
drastically reduced due to the extended irradiated volume which is now partly composed of
normal tissue from the surrounding OARs. Nonetheless, as for V95 and homogeneity, 4DN and
4D0 calculations yield similar results, meaning again that interfractional changes are correctly
compensated.
Extending the irradiated volume causes indeed an increase in V20 values but which is not
so important. It is never higher than 10%, meaning enlarging target contours do not cause
a major change in the irradiation of OARs. However, if the SFITV and the 3FPTV cases are
compared, the increase becomes quite large in the case of the ipsilateral lung, which is quite
normal considering both extended volume and more fields used, resulting logically in more
dose in the ipsilateral lung. But, again, V20 does not specifically represent high dose regions and
looking at dose distributions displayed on figures 3.12.a-f permits to see the great advantage
of using three fields combined with additional margins. It allows obtaining a conformal dose
distribution, with a target which is completely and homogeneously covered, and reduced high
dose regions outside the tumor. Once again field directions can be chosen differently to avoid
or decrease further the irradiated volume of lung visible on figures 3.12.g-i. Moreover overdose
due to the use of three fields and also visible on figure 3.12.i (the pink area besides the tumor)
is disappearing when the optimal contour extension value is used in TRiP4D.
To conclude this last part, looking at figure 3.13 shows that the best combination (3 fields,
large focus, short GW and PTV margins) is able to mitigate efficiently the tumor motion and
size dependences of V95 and homogeneity and CN, respectively, as well as provide conformal
fraction treatment, represented by the obtained high V95, good homogeneity and acceptable
CN. V107, if a correct contour extension is chosen, is also close to 0. However, comparison with
other mitigation techniques is a topic of interest which will be developed in the next chapter to
investigate further possible improvement of the tumor treatment and reduction of the irradiation
in the OARs.
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4 Comparing motion mitigation techniques
using optimized parameters
4.1 Introduction
In the previous chapter, using a combination of three fields and a range-based ITV with PTV
margins composed of 3mm (geometrical) isotropic margins and 3mm+3% (water equivalent)
range margins, a large focus (15 mm, FWHM) and a short gating window (GW, 11.9% of the
amplitude) yielded the best results in terms of dose coverage and homogeneity. The best con-
formity number (CN) values were obtained using 3 fields combined to ITV margins alone and
deteriorated when adding PTV margins. Now, even though gating has shown good conformity,
whether it was performed clinically combined to passive beam delivery (Tsujii et al., 2004; Iwata
et al., 2010; Tsujii and Kamada, 2012) or simulated with active beam scanning like in the pre-
vious chapter, further investigation was a necessary step to determine if this technique was the
best suited to mitigate intrafractional motion and interfractional anatomic changes using only
one plan optimized with the first weekly 4DCT.
Thus, it was decided to do a comparison of the results yielded using gating with other tech-
niques such as rescanning only or a combination of rescanning and gating, referred to as re-
gating. Rescanning has indeed shown interesting results for protons: varying the number of
rescans as well as some other treatment parameters such as field directions was done by Knopf
et al. (2011), resulting in a more significant effect of this mitigation technique when less fields
were used and in a satisfactory homogeneity obtained after only a few rescans. It was however
stated that large motion amplitude tumors may require rescanning to be combined with another
mitigation technique such as gating or breath-hold. The rescanning method used in this paper,
referred to as perfect rescanning (PRSC), was different compared to the normal rescanning pro-
cess because its principle was to deliver homogeneously one tenth of the dose to each one of
the 10 motion states of the 4DCT. Thus it only allowed studying the effects of tumor motion
without interplay effects by delivering a fraction of the dose to each motion state.
Furukawa et al. (2007, 2010) also proposed a method combining rescanning and gating,
called phase controlled rescanning, whose principle is to deliver rescans inside the gating win-
dow. This method was tested experimentally and showed encouraging results with an obtained
4D dose delivery quite similar to the one obtained in the static case, proving that this method
could be used efficiently to compensate for tumor motion (Mori et al., 2013a,b). The so called
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perfect regating (PRGT) technique used here borrowed the same idea of combining gating and
rescanning, meaning that the previously described PRSC method was modified so that one third
of the planned dose was delivered homogeneously to 3 of the 10 motion states. Interplay effects
were thus again ignored.
In this chapter, gating simulations, which were performed again (see appendix D), were com-
pared to results obtained using perfect rescanning and perfect regating. The aim was to de-
termine if a further increase in target dose conformity and better organ at risk (OAR) sparing
were achievable. The three motion mitigation techniques were used in combination with the
optimized parameters found in the previous chapter.
4.2 Materials and methods
4.2.1 Patient cohort
In this chapter, 6 patients from the 9 described in chapter 3 were used to compare motion
mitigation techniques: patients 1, 2, 3, 7, 8 and 9. As preliminary simulations with the remain-
ing patients 4, 5 and 6 showed good results (see appendix E.1 for the detailed patient results
obtained in 3), no matter which configuration was used, they were excluded to allow for a
larger set of simulation parameters in the given time frame. Thus it was decided to focus on
the patients showing large motion and/or small size tumors, meaning that, for the 6 chosen
patients, a total of 44 weekly 4DCTs were used. Number of weeks for each patient, alignment
and registration methods and fields are the same as presented in the previous chapter.
4.2.2 Treatment parameters
In this chapter, comparison of gating, rescanning and regating was done using optimized
parameters isolated in the previous chapter, as described above in the introduction. Thus, only
one gating window (GW, 11.9% of the amplitude) was used for gating and three fields (see
chapter 3) combined to PTV margins (3FPTV case of chapter 3) were used for each motion
mitigation case. However, 3 different foci (6, 10 and 15 mm, FWHM) were used again. As in
the previous chapter, the distance between each raster position was set to 2 mm on each iso-
energy slice (IES) and the distance between two IESs was set to 3 mm water-equivalent using a
ripple-filter (RiFi) of 3 mm (Weber and Kraft, 1999).
4.2.3 Gating
All gating plans were simulated using the GSI 4D treatment planning system (4DTPS) TRiP4D
(Richter, 2012), based on TRiP98 and modified to allow 4D-dose calculations. The gating pro-
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cess used in this chapter is also the same as in the previous one. To obtain each 4D beam delivery
sequence, a motion surrogate, the optimized static treatment plan and the accelerator specifica-
tions (synchrotron of HIT in this case) are necessary. The motion surrogate and the optimized
plan are used to distribute the dose delivery among the selected motion states corresponding
to the GW and accelerator specifications add the interplay effects by simulating the dynamic
behavior of the accelerator, such as the scanning speed. Thus, 4D gating simulations contain
the two dynamic systems necessary to simulate interplay effects: the moving tumor and the 4D
gating plan delivered using a realistic accelerator behavior (Richter, 2012). In this chapter, 4D
simulations were performed using a contour extension of 1.1 instead of 0.35, as recommended
by Weber (1996) (see appendix D). But, except for this value, the motion surrogate (sine square
with a unique period 3.6 seconds) and the ITV definition (range corrected ITV composed of 5
motion state CTVs representing 25% of the amplitude) were the same as in the previous chapter.
For each patient, plans were initially optimized to this ITV computed with the first week’s CT,
using one unique planned dose of 8.1 Gy(RBE).
4.2.4 Perfect rescanning (PRSC)
All rescanning plans were also simulated using TRiP4D (Richter, 2012). However, the sim-
ulation process is different compared to gating: first the optimized plan was generated using
an ITV which was composed of all ten motion states of the 4DCT, then the main principle of
the rescanning process used here is to deliver homogeneously and identically one tenth of the
planned dose (see figure 4.1) to each one of the ten motion states of the 4DCT. So, here, no
motion surrogate is used and the dose of each raster point of the static treatment plan is divided
by 10 and distributed identically on all 4DCT states. Thus, because there is no double dynamic
system as for gating, interplay effects are not taken into account.
4.2.5 Perfect regating (PRGT)
Regating plans were simulated using TRiP4D (Richter, 2012). Even though the optimized
plans were those that were computed for gating, because the ITV is identical, the technique
is again different compared to gating and more similar to the rescanning process described
above. Indeed the difference with PRSC is here that one third of the planned dose is delivered
homogeneously to only 3 motion states which compose the GW (see figure 4.1). Those 3 motion
states correspond to the GW that was used for gating. Therefore, again, interplay effects are
ignored because of the absence of a double dynamic system.
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Figure 4.1.: Diagrams of the perfect rescanning (PRSC) and perfect regating (PRGT) techniques
dose delivery. Motion state n°5, set as the reference state, represents the end-exhale
state. In the case of PRSC, one tenth of the dose is delivered to each motion state of
the target and in the case of PRGT, one third of the dose is delivered to each one of
the three motion states composing the GW. Interplay is not taken into account for
both techniques.
4.2.6 Data analysis
For each mitigation technique, the dose distribution of each week was obtained by accu-
mulating the dose delivered to each motion state on the reference phase of the 4DCT using
state-to-state non-rigid vector fields. Comparison of the obtained accumulated dose between
the three mitigation techniques was then done by investigating differences in target coverage
(V95), overdose (V107), homogeneity and conformity number (CN) for the tumor and V20 and
maximal dose point (MXD) for the surrounding organs at risk.
For each comparison, a Wilcoxon signed-rank test (W ) was performed using a level of signifi-
cance of 0.05 to estimate the difference between two samples. In the case of samples containing
more than 10 values, the p-value (p) was computed using the obtained z-score (z).
4.3 Results
All results were simulated on the weekly 4DCTs with a planned dose of 8.1 Gy(RBE). In all
following figures the average value (marker), the median value (horizontal bar in the box), the
25th and 75th percentile and the total range of all values are given. More details about the
planned, static dose on the first week (3D0), the 4D dose on the first week (4D0) and the 4D
dose on all following weeks (4DN) can be found in the previous chapter.
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4.3.1 Gating and PRSC
Results obtained using gating and PRSC in terms of target coverage (V95), overdose (V107),
homogeneity and CN can be observed on figure 4.2.
3D0 simulations yield very similar results (z < zcri t ical) in terms of V95 with an average value
higher than 99.9% for both cases. Overdose is also similar (z < zcri t ical), even though the max-
imal value is a bit higher in the case of gating. It is the same for homogeneity, whose average
values are similar in both cases (z < zcri t ical), but whose maximal values are different with a
higher one for gating at 7.3% and a lower one for PRSC at 4.2%. Only CN shows a significant
difference (p < 0.05), illustrated by an average value 14% higher in the case of PRSC at 0.49
compared to 0.43 obtained with gating as well as higher minimal and maximal values (0.42
compared to 0.38 and 0.64 compared to 0.56, respectively).
4D0 simulations show that rescanning permits to obtain better values in terms of target cov-
erage (p < 0.05). V95 values are indeed almost identical to values obtained for 3D0 in the case
of PRSC, as shown by an average value higher than 99.9% (minimum: 99.8%), while the mean
V95 decreases to 99.4% (minimum: 97.0%) in the case of gating. Homogeneity and CN are bet-
ter (p < 0.05) in the case of PRSC, illustrated by average values of 2.4% and 0.52, respectively,
compared to 4.4% and 0.44 obtained in the case of gating. On the contrary, overdose is slightly
better in the case of gating (W <Wcri t ical).
Finally, 4DN simulations show the largest differences. V95 appears to be better in the case of
gating compared to PRSC (p < 0.05), illustrated by mean values of 97.0% and 96.2%, respec-
tively. V107 is almost identical in both cases (z < zcri t ical) and close to 0. And again, homogeneity
and CN are better in the case of PRSC (p < 0.05), as shown by mean values of 4.3% and 0.49,
respectively, compared to 5.2% and 0.43 obtained with gating. On figure 4.4, the dose volume
histogram (DVH) of the CTV is displayed for patient 2 and for the two techniques. It shows that
results are indeed very close and, depending on the week, slightly better for one technique or
for the other one. The patient-specific weekly results can also be seen in appendix E.2 and show
that gating generally yields better V95 and homogeneity and PRSC better CN.
Figure 4.3 shows results obtained using gating and PRSC regarding the dose delivered to the
OARs. Even though those results are close to each other, some trends can be isolated. Con-
cerning the esophagus, V20 is similar using both mitigation techniques (z < zcri t ical). For all the
other organs at risk, V20, even though the distributions look very similar in both cases, signifi-
cant trends can be pointed out (p < 0.05): in the case of the heart, the ipsilateral lung and the
contralateral lung, PRSC yields better results while in the case of the spinal cord, gating permits
to obtain lower V20 values.
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Figure 4.2.: Comparison of V95, homogeneity, V107 and CN obtained using gating, PRSC and
PRGT. Each 3D0 bar is composed of 18 datapoints, representing static simulations
done with 3 foci using week 0 of each patient (3D0 simulations were not performed
in the case of regating). 4D0 bars are also composed of 18 datapoints, represent-
ing 4D simulations done with 3 foci and one GW in the case of gating using week 0
of patient. 4DN bars are composed of 114 datapoints, representing 4D simulations
done with 3 foci and one GW in the case of gating using week 1 to 5-8 of each
patient (see previous chapter for specifications concerning 3D0, 4D0 and 4DN).
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Concerning the maximal point dose, values are also similar from one mitigation technique
to the other but, except for the spinal cord (z < zcri t ical), all the other organs show again
a significant behavior (p < 0.05) when the two mitigation techniques are compared. Thus,
using PRSC permits to obtain slightly lower MXD for the esophagus, the heart and the ipsi- and
contralateral lungs.
Figure 4.4 shows that different trends can be observed depending on the chosen dose interval.
For instance, in the case of the ipsilateral lung, gating and PRSC yields similar results on a dose
interval going from 0 to 30% while gating permits to obtain better results above 30% of the
dose. In the case of the spinal cord, the global trend described above for V20 is respected with
better values obtained on the entire dose distribution in the case of gating.
Figure 4.6.a-c and 4.6.d-f show static and 4D dose distributions obtained using the 1st and
the 7th weekly CTs of patient 3 and gating and rescanning as motion mitigation techniques,
respectively.
4.3.2 Gating and PRGT
Figure 4.2 also shows results obtained for gating and PRGT. 3D0 simulations were only
performed for gating because the same optimized plan was used for both motion mitigation
techniques. The results in terms of V95, V107, homogeneity and CN are already described in the
previous section. PRGT yields better results for 4D0 simulations in terms of V95 and homogene-
ity (p < 0.05), with 100% and 2.3% as average values, respectively, compared to 99.4% and
4.4% obtained for gating. Compared to 3D0 simulations done for gating, PRGT 4D0 simulations
yield almost the same results with almost perfect V95, very low V107 and lower homogeneity (see
figure 4.2). Comparing overdose and CN, better results are obtained using PRGT for the first
one (W >Wcri t ical) and gating for the second one (p < 0.05).
4DN simulations, no matter whether gating or regating is used, show drastically decreased
minimal values and lower average values concerning V95 compared to 3D0 and 4D0 simula-
tions. Respectively, for gating and PRGT, minimal values drop to 72.0% and 75.0% and average
values, which were higher than 99% for 3D0 and 4D0 simulations, are reduced to 97.0% and
98.0%. Homogeneity follows the same behavior and is degraded, meaning slightly higher mean
values and much higher maximal values, while CN shows larger ranges (see figure 4.2). Now,
comparing the results of the two motion mitigation techniques, they both yield similar results
and trends can be observed as PRGT yields better V95, V107 and homogeneity (p < 0.05) while
gating permits to obtain better CN (p < 0.05). Better V95 in the case of PRGT can indeed be
observed in the case displayed on figure 4.4 and in appendix E.2, where detailed weekly results
are available.
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Figure 4.3.: Comparison of V20 and the maximal point dose obtained using gating, PRSC and
PRGT. Each bar is composed of 132 datapoints obtained from all 4D calculations
(4D0 and 4DN, all weeks of all patients) performed using 3 foci (and one GW in the
case of gating).
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Figure 4.3 also shows results obtained using gating and PRGT concerning the dose delivered
to the organs at risk. Like in the previous section where V20 and MXD were similar for gating
and PRSC, V20 and MXD results are here again similar but showing significant trends (p < 0.05)
when the two techniques are compared. Thus, for each OAR, PRGT permits to obtain lower V20.
MXD values also show very little differences but, as well as for V20, PRGT yields lower MXD
values in the case of each OAR (p < 0.05).
Figure 4.4 shows that, for patient 2 and for both displayed OARs, dose distributions are indeed
very similar and, depending on the dose percentage in the DVH, slightly better results can be
obtained using one technique or the other.
Figure 4.6.a-c and 4.6.g-h show static (only for gating) and 4D dose distributions obtained
using the 1st and the 7th weekly CTs of patient 3 and gating and PRGT as motion mitigation
techniques, respectively.
Figure 4.4.: Dose volume histogram (DVH) showing the difference in dose delivery to the CTV,
the ipsilateral lung and the spinal cord for gating (red), PRSC (blue) and PRGT (green)
using patient 2 weekly 4DCTs. Results for the 6 weekly 4DCTs and for each mitiga-
tion technique are displayed using a configuration composed of a focus width of 15
mm (FWHM) and a GW of 11.9%. The two weekly CTV DVHs which show a decrease
at about 30% of the dose are the consequence of large interfractional anatomic
changes displayed on figure 4.5.
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4.3.3 PRSC and PRGT
The last possible comparison using figures 4.2 and 4.3 can be done between the PRSC and
regating methods.
Looking at 4D0 simulations, the two mitigation techniques yield again similar results and
the only significant differences can be observed for overdose and CN. Indeed PRGT permits to
obtain lower V107 (p < 0.05) but both techniques yield very close values lower than 1.5%. Then
PRSC yields higher CN (p < 0.05), as illustrated by mean values reaching 0.52 in the case of
PRSC and only 0.43 in the case of PRGT.
Figure 4.5.: Overlaid 4DCTs of patient 2: case a represents weeks 0 and 4 and case b weeks 0 and
5. Large interfractional anatomic changes can be seen which lead to the decrease in
target coverage visible on figure 4.4.
In the case of 4DN simulations, similar trends are observed compared to 4D0 calculations,
which were already described in the previous subsections and comparing the two mitigation
techniques, using PRGT allows obtaining better results (p < 0.05) in terms of target coverage,
overdose and homogeneity. This can be observed on figure 4.2 with average V95 and homogene-
ity values of 98.0% and 3.3% for PRGT compared to 96.2% and 4.3% for PRSC. V107 values
are in each case lower than 1%. And the best CN is yielded by PRSC (p < 0.05). Once again,
depending on the week, figure 4.6 shows that different trends concerning the dose delivered
to the CTV can be observed, but looking at weekly results in appendix E.2 permits to see that
PRGT yields the best V95 and homogeneity while PRSC permits to obtain better CN.
Figure 4.3 permits to see that the dose delivered to the OARs is again very similar using one
technique or the other but for some organs, a trend can be isolated when comparing the PRSC
and regating methods. Then using PRSC yields lower V20 values (p < 0.05) in the cases of
the heart and the ipsi- and contralateral lungs. On the contrary, using PRGT permits to obtain
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lower V20 (p < 0.05) in the spinal cord. Both techniques yields similar results in the case of the
esophagus (z < zcri t ical).
Figure 4.6.: Dose distributions obtained using different motion mitigation techniques. First line
is composed of gating simulations, second line of rescanning simulation and third
line of regating simulations. First column represents examples of 3D0 simulations,
second column 4D0 simulations and third column 4DN simulations. 3D0 and 4D0
simulations were done using week 0 of patient 3 and 4DN week 6 of patient 3. Be-
cause the optimized plan was the same for gating and regating, the static simulation
(3D0) was not repeated for regating. All displayed dose distributions used 15 mm as
beam focus (FWHM).
Now, looking at the maximal point dose, using PRSC yields lower MXD values (p < 0.05) in
the case of the heart and the ipsi- and contralateral lungs. The difference between the values
obtained the two techniques in the cases of the esophagus and the spinal is not significant (z <
zcri t ical). Figure 4.4 shows that PRGT results are very close to the ones obtained using gating.
Thus the comparison of PRGT with PRSC is the same as the one explained in the gating/PRSC
comparison, showing slightly better results for one technique or the other depending on which
dose interval is observed.
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Figure 4.6.d-f and 4.6.g-h show static (for PRSC) and 4D dose distributions obtained using the
1st and the 7th weekly CTs of patient 3 and PRSC and PRGT as motion mitigation techniques,
respectively.
4.4 Discussion
In this chapter, relevant patient-4DCT datasets showing large tumor motion and/or small
tumor size, representing 6 of the 9 patients in the series of 4DCTs, were used to investigate
which motion mitigation technique among gating, perfect rescanning (PRSC) and perfect regat-
ing (PRGT) yielded the best results. While gating permits to study the effects of intrafractional
motion and interplay on the dose delivery, PRSC and PRGT do not take into account interplay
effects. Weekly treatment simulations were performed using optimized parameters found in the
previous chapter, such as the width of the focus or PTV margins.
Looking at results obtained using gating, PRSC and PRGT, it is possible to estimate the effect
of both interfractional changes and intrafractional motion on the quality of the tumor treatment
given by each motion mitigation technique. Even though it is only partially feasible in the case
of the PRSC and regating methods, due to the fact that interplay effects are not taken into ac-
count and the tumor motion is only simulated using the ten states of each 4DCT and three states
for PRSC and PRGT, respectively, it permitted to do a first comparison.
Results show that, globally, the three motion mitigation techniques were able to compensate
identically for tumor motion and anatomic changes from one fraction to the next one. Although
significant trends could be observed, the amplitude of the differences between results obtained
using different techniques was never large, as illustrated by their distributions on figure 4.2 and
the DVHs on figure 4.4. Only the conformity number showed a significant and large difference,
PRSC yielding higher values than gating and PRGT. This can be due to the fact that treatment
plans used for gating and PRGT were optimized on an ITV composed of 5 motion states and that
the 4D dose delivery was then performed using only a 11.9% GW (corresponding to 3 motion
states). This can lead to dose delivery outside the target because the planned volume was too
large. V95 and homogeneity, except for 4D0 simulations, behaved the exact same way for the
three mitigation techniques. Even though gating plans were only optimized on ITVs composed
of 5 motion states, static simulations yielded excellent results for all three methods with almost
perfect V95 and good homogeneity for most of the cases (figure 4.2). Looking at the results ob-
tained for 4D0 simulations using PRSC and PRGT, it is clearly visible that interplay effects were
not taken into account when they are compared to the results obtained using gating. Despite
the fact that V95 and homogeneity average values are quite satisfactory in all cases, it is possible
to see the effects of intrafractional motion combined to interplay by looking at the minimal V95
value and the maximal homogeneity value obtained using gating, which were degraded com-
pared to the corresponding extrema obtained using PRSC and PRGT (figure 4.2).
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Now, 4DN simulations show that interfractional changes can have a huge impact on target
coverage and homogeneity, potentially higher than intrafractional tumor motion and interplay.
Discussing the choice of a rescanning method, Seco et al. (2009) stated that interplay effects
are mainly responsible for non-systematic errors in dose distribution. However, looking at 4DN
simulations on figure 4.2, although interplay effects are not taken into account in the cases of
the PRSC and regating methods, the V95 minimal values and the homogeneity maximal values
are drastically reduced and increased, respectively, like for gating, compared to 4D0 simula-
tions. The impact on CN is also noticeable for all three techniques, 4DN simulations yielding
larger distributions showing roughly the same maximal value but a lower minimal value than
for 3D0 and 4D0 simulations. Sonke et al. (2008) also pointed out that, while intrafractional
motion was quite stable from one fraction to another, large interfractional variability could be
sometimes observed. Indeed, looking at the weekly and patient specific results in appendix
E.2, weekly cases can be observed, which show lower V95 and CN, and higher homogeneity
and which correspond to weekly CTs for which interfractional anatomic changes, such as organ
drifts or tissue shifts, are present. Those weekly cases were already observed in the previous
chapter using gating whose results are also displayed on figure 4.2. The latter shows that V95,
CN and homogeneity are affected the same way by interfractional changes, no matter whether
PRSC and PRGT is used as alternative technique. Then, comparing the changes between the
three motion mitigation techniques, the largest difference can be observed for CN whose values,
as described and explained above in the case of 4D0 simulations, are again higher in the case of
PRSC. Moreover, as 4DN simulations show V95 average values of 97% and 98% for gating and
PRGT, respectively, and as intrafractional motion was already compensated efficiently using the
parameters found in chapter 3, it can be assumed that interplay effects are the cause of the 1%
difference. Therefore, using rescanning, which is particularly effective to compensate for these
interplay effects (Rietzel and Bert, 2010), would not result in a significant improvement.
Concerning the irradiation of the OARs, the three mitigation techniques showed again similar
results no matter whether one looks at the V20 or at the maximal point dose (figure 4.3). Some
trends were identified but the amplitude of the differences between results was not large (figure
4.4). Thus, despite the fact that high dose regions may be a bit larger in the case of gating and
PRGT, as previously shown by a lower CN, intermediate dose regions are roughly identical as
well as maximal values. Because interplay effects are not taken into account in the rescanning
and the regating processes used in this study, the similarity between the results obtained using
gating, PRSC and PRGT shows that interplay does not impact severely the dose delivered to the
OARs, at least when optimized treatment plan parameters are used.
Comparing gating, PRSC and PRGT showed that the three techniques globally yielded simi-
lar results, in terms of target coverage and organ irradiation, as shown by figure 4.6 on which
no significant difference between the three techniques for static and 4D dose distributions can
be observed. Even though some patient specific behaviors can be observed (figure 4.4 and ap-
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pendix E.2), the differences are never large. Moreover, 4DN dose distributions displayed on
figure 4.6 also permit to estimate the importance of interfractional anatomic changes by looking
at the shape of the high-dose regions compared to the ones displayed on 4D0 dose distributions.
This leads to think interfractional changes actually have a more important negative impact on
treatment delivery than intrafractional tumor motion and interplay when a unique treatment
plan is generated using the first weekly 4DCT.
To conclude this chapter, it has been shown that PRSC and PRGT do not allow a relevant im-
provement in the results compared to gating, no matter whether one looks at the dose delivered
to the tumor or to the surrounding tissue. Moreover, it seemed that interplay had a much less
significant impact on dose delivery than interfractional anatomic changes, which could be due
to the fact that the intrafractional tumor motion amplitude is smaller than 5 mm for 6 patients
out of 9. Thus, gating remains a better solution to mitigate motion using only one optimized
plan over the whole course of the treatment.
Now, Hui et al. (2008) performed similar weekly simulations using a single treatment plan
with protons and recommended to use adaptive replanning for cases showing large interfrac-
tional anatomic changes. A replanning factor based on the amplitude of interfractional variabil-
ity could permit to decide, for each new fraction, whether a new treatment plan is needed or
not. Also, using gating, it only remained to determine if some field angles could be found, for
which interfractional range differences would be minimized, and if a replanning factor could
be isolated, with which it would be possible to know, for each treatment fraction, if a new opti-
mized plan was necessary. Then it was possible to simulate a clinical treatment for the 9 patients
which were available. Therefore, the next and last chapter will focus on the search of optimized
field angles and of a replanning factor, followed by this clinical treatment simulation relying on
treatment schemes described by Miyamoto et al. (2003, 2007) and adapted for the number of
available weekly CTs for each patient using the biological effective dose equation.
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5 Simulation of a clinical optimized
treatment scheme
5.1 Introduction
The two previous chapters permitted to isolate optimized parameters and to determine that
gating allowed obtaining the best results compared to rescanning and regating processes for
which interplay was not taken into account. The last chapter also showed that interfractional
changes, such as patient misalignments or organ drifts, were responsible for major dose de-
livery deterioration, potentially more significant than negative effects caused by intrafractional
motion or interplay. Besides, as described above, the two previous chapters aimed at studying
the influence of treatment planning parameters or mitigation techniques on dose delivery, but
only on a weekly basis with no clinical consideration.
Thus, knowing which parameters permit to compensate best for intrafractional motion as well
as interfractional changes and which motion mitigation technique can realistically be used, it
was decided to simulate a clinical study using the conclusions of the two previous chapters.
Using a fractionation scheme corresponding to the number of weekly 4DCTs available for each
one of them, patients of the cohort underwent a patient-specific treatment simulation. The final
goal was to observe, at the end of the treatment, the total dose delivered to the tumor as well
as to the organs at risk and the surrounding tissue.
To perform such a study, clinical information is needed, such as potential optimal field an-
gles, treatment schemes and fractionation or organ dose limits. Some studies give details about
different clinical treatment protocols performed for instance at NIRS or at Massachusetts Gen-
eral Hospital (MGH) (PTCOG; Miyamoto et al., 2003, 2007). Information about fractionation
schemes, motion mitigation techniques, beam delivery systems or follow-up visits is detailed.
However, information about patient setup such as gantry or couch angles is not available. Op-
timal patient setup is important, because it can allow better critical structures sparing in the
patient’s body and still obtain good treatment delivery. This is part of uncertainties and start-
ing conditions while generating a treatment plan. Those have been studied (Lomax, 2008a,b;
Albertini et al., 2010, 2011) and while effects of interfractional changes were addressed by
Lomax (2008b), the possibility of using field angles more robust to interfractional variability
was not suggested. Thus, it was decided to see if it was possible to isolate preferential field
angles or directions, which would be less affected by interfractional variability while avoiding
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critical structures and which would then be used in the final clinical simulations. Interfractional
changes, potentially responsible for large dose delivery errors, have also directly been studied
(McClelland et al., 2011; Hui et al., 2008; Sonke et al., 2008) and it was shown that it can re-
sult in large differences causing themselves a negative impact on dose delivery. Using only one
treatment plan for the entire course of treatment results indeed in severely deteriorated dose
delivery for some fractions, as shown in chapter 3. The idea of a replanning factor was thus here
investigated so that, just by comparing information about the planning week and the following
ones, it could be decided to recalculate a new treatment plan if changes were too important.
Such a factor could then also be used in the clinical simulations.
During a treatment, toxicity in the organs at risk (OARs), well described by Cox et al. (1995),
should be avoided. To prevent reactions due to overdose in the OAR, dose limits were set for
conventional radiotherapy treatments (Grimm et al., 2011; RTOG, 2014). But Grimm et al.
(2011), by quoting a lot a different references, shows that very different values are used from
one study to the other and, even though those values are accepted and are set by professional
clinicians, Benedict et al. (2010) stated that they are mostly unvalidated. Nevertheless, some
of those OAR dose limits, all coming from RTOG (2014), were used in this study to set organ
constraints in the treatment plan optimization process.
Therefore, in this chapter, before the clinical simulation was performed, two brief studies aim-
ing at isolating first a replanning factor and second optimal field directions were carried out.
Then, using optimized parameters found in chapter 3 and gating, each patient 4DCT dataset
was used to investigate the total dose distribution at the end of a fractionation personalized
treatment.
5.2 Materials and methods
5.2.1 Patient cohort
The same dataset of 9 NSCLC lung tumor patients from MDACC (The University of Texas MD
Anderson Cancer Center) (Britton et al., 2007) was used as in the last chapter (see chapter 3
for more details). Number of weeks, motion amplitude, angles for multiple fields calculations,
planned doses per fraction and in total are listed in table 5.1.
5.2.2 Influence of the weekly range difference on target coverage
Chapter 3 permitted to find treatment planning optimized parameters in order to obtain sat-
isfactory target coverage and chapter 4 confirmed gating was the best mitigation technique
compared to the perfect rescanning and regating processes.
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Table 5.1.: Description of the 9 NSCLC Patients from MDACC (see figure 5.1 for field angles il-
lustration): patient number, number of weeks available, average motion amplitude,
field angles for multiple fields calculations (SFUD1, 2 and 3), planned dose per frac-
tion and in total. Dose fractionation schemes are detailed in the next section.
Angles [degree] Dose [Gy(RBE)]
Patient Weeks Motion [mm] SFUD1 SFUD2 SFUD3 per fraction Total
1 8 3.4 130 180 250 8.6 68.8
2 6 8.6 0 40 310 10.3 61.8
3 9 10.1 90 280 320 8 72
4 8 3.3 180 225 270 8.6 68.8
5 10 4.1 0 50 270 7.4 74
6 8 1.8 0 50 300 8.6 68.8
7 7 1.6 140 180 270 9.3 65.1
8 8 4 90 180 270 8.6 68.8
9 6 23.5 90 140 230 10.3 61.8
Figure 5.1.: Directions of the four main field angles. Values listed in table 5.1 can be visualized
using those four main directions.
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However, even when optimized parameters were used, some weekly cases showed deterio-
rated dose delivery due to interfractional changes resulting in range differences between the
first week and the next ones. Thus, before carrying out the new simulations using appropriate
treatment schemes, a brief study was performed in order to determine if, just by knowing the
range difference between the planning week and the following fractions, it could be possible to
predict the resulting target coverage. The latter being then known, it could be possible to decide
if replanning would be necessary or not for the concerned fraction.
To isolate such a replanning factor, the target coverage difference between week 0 and week
N single field calculations using ITV margins only (SFITV configuration in chapter 3) was com-
puted. It was compared to the difference of the corresponding weekly water-equivalent tumor
median ranges in the field direction (see field angles in table 5.1). Those ranges were indeed
computed for each of the ten 4DCT motion states by calculating, for each voxel of the clinical
target volume (CTV) located on the path the beam, its water-equivalent range and then finding
the median value. The 3 foci and 3 GW used in chapter 3 were used and the range difference
was computed for each of the 10 motion states of each weekly 4DCT.
5.2.3 Investigating field angles
Following the determination of a possible replanning factor using weekly water-equivalent
tumor range differences, another brief study was performed in order to investigate if some field
angles are less affected by interfractional changes.
For each of the 9 patients, the water-equivalent tumor median range difference between the
planning week and the following ones was computed for 18 different gantry angles 10° apart
from each other. This allowed covering the patient lateral tumor side, meaning the side corre-
sponding to the tumor location. This was done for the reference phase of each weekly 4DCT
and displayed on polar graphs (see appendix E.3), representing a total of 70 weekly polar distri-
butions. The average weekly range difference was computed for each patient and displayed in
a new polar graph to compare patient-specific results. Those were then analyzed to determine
if general field directions can be isolated, which show minimal range differences.
5.2.4 Clinical simulations
To investigate the validity of the optimized parameters found in chapter 3 combined to gating
in a clinical treatment, new simulations were carried out. Those optimized parameters consisted
in a large focus (15mm, FWHM), a short gating window (GW, 11.9% of the motion amplitude),
3mm isotropic (geometrical) and 3%+3mm range (water-equivalent) margins and 3 fields. The
same principle of one treatment plan applied to the following fractions was used, but appro-
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priate treatment schemes, such as the planned dose, field angles or organ constraints were this
time taken into account.
5.2.4.1 Treatment schemes
Miyamoto et al. (2003, 2007) reported results of treatment of NSCLC tumors at NIRS using
carbon ion therapy. A total dose of 72 Gy(RBE) was delivered over 3 weeks in 9 fractions of 8
Gy(RBE) each. This scheme was used as a basis to calculate patient dedicated schemes in this
study. To do so, the equivalent effective dose in 2 Gy(RBE) fractions (ED2Gy(RBE)) was computed
using the following equation (IAEA, 2008).
ED2Gy(RBE) =
DxGy(RBE)

x + αβ

2+ αβ
 (5.1)
where x corresponds to the desired dose per fraction and DxGy(RBE) to the total dose over the
whole treatment. The ratio α/β was set to 6 Gy, in accordance with RBE studies done at GSI,
themselves using results coming from clinical studies in Marburg and in Japan (Kanai et al.,
2006), even though the latest studies (Elsaesser and Scholz, 2007; Kase et al., 2008) used a
value closer to 5 Gy. In the case of the fractionation scheme described above (9 fractions of
8 Gy(RBE), total dose of 72 Gy(RBE)), an equivalent dose (ED2Gy(RBE)) of 126 Gy(RBE) was
found. Now, knowing the number of fractions per patient for this study (column 2 of table 5.1)
and using DxGy(RBE) = nx in equation 5.1 (n being the number of fractions), it was possible
to determine the appropriate dose per fraction x for each patient so that ED2Gy(RBE) was equal
to 126 Gy(RBE) simply by resolving the following second degree polynomial (obtained from
equation 5.1):
nx2 + n
α
β
x − ED2Gy(RBE)

2+
α
β

= 0 (5.2)
Taking the positive solution of the polynomial in equation 5.2 permitted to obtain the values
listed in the seventh column of table 5.1 for each patient and then to calculate the total doses
listed in column 8 by just multiplying the weekly dose by the number of weeks.
5.2.4.2 Optimization and 4D calculations
As in the two previous chapters, treatment plans were generated using the first weekly 4DCT
of each patient using TRiP4D (Richter et al., 2013). Plans were optimized on a WEPL-ITV (Gra-
eff et al., 2012) composed of 5 motion states CTVs, representing 25% of the motion amplitude.
Parameters found as optimal in chapter 3 were used, meaning a focus of 15 mm (FWHM), a
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gating window corresponding to 11.9% of the amplitude, three fields (see table 5.1 for field
angles) and a combination of isotropic (3mm geometrical) and range (3mm+3% water equiva-
lent) margins.
For all simulations, the motion surrogate was defined according to Lujan et al. (1999), i.e. a
sine square with a unique period of 3.6 seconds and 0 degree as starting phase. As explained
in chapter 3, only one starting phase was studied because, due to gating, beam delivery for
different starting phases is quickly synchronized after the first few spills of the synchrotron ac-
celerator, thus calculations yield very similar results for different starting phases. As other fixed
treatment parameters, the lateral distance between raster positions was set to 2 mm on each
iso-energy slice (IES) and the distance between two IESs was set to 3 mm water-equivalent us-
ing a ripple-filter (RiFi) of 3 mm (Weber and Kraft, 1999).
In the case of the esophagus and the heart, organ constraints were also added to limit the
maximal dose delivered to the OARs to 40% of the planned dose. This percentage used for each
patient permitted to obtain at least a maximal dose in the OARs below or slightly above the
corresponding maximal dose limits listed in table 5.3. This was the result of a trade-off between
conformal target dose delivery and OAR sparing. The weight for each organ was set so that both
the tumor and the organ would have equal weight in the optimization process of the treatment
plan computation.
5.2.4.3 Calculation of the total dose
Computation of the total dose to investigate the quality of the whole treatment was done by
using vector fields obtained from the deformable registration between the first week (used to
generate the treatment plan) and each following one. Each weekly dose distribution obtained
after the 4D calculations was deformed to match the anatomy of the planning 4DCT. They were
then added to obtain the total treatment dose distribution (Janssens et al., 2009).
5.2.5 Data analysis
The dose distribution of each week was obtained by accumulating the dose delivered to each
motion state on the reference phase of the 4DCT using state-to-state non-rigid vector fields.
Then, the total dose was accumulated as described in the previous section. As in chapters 3
and 4, target coverage (V95), overdose (V107), homogeneity and the conformity index (CN)
were investigated to estimate the quality of the dose delivery for the static calculations us-
ing the planning CT (3D0), 4D calculations using the planning 4DCT (4D0) and the following
weekly 4DCTs (4DN) and the total treatment calculations (total) obtained by adding all de-
formed weekly dose cubes.
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Table 5.2.: Organ volume/dose limits for a 5*10Gy(RBE) treatment scheme from RTOG (2014)
adapted for each fractionation scheme. Adaptation of the values was done with an
α/β ratio of 3 for the heart, the spinal cord and the lungs and 10 for the esopha-
gus, corresponding to late- and early-responding tissues, respectively (Hall and Gar-
cia, 2011). In the case of the spinal cord and the lungs, two different OAR limits were
available, written here as 1 and 2.
Dose for each number of fractions [Gy(RBE)]
Organ Volume [cc] 5 (RTOG, 2014) 6 7 8 9 10
Esophagus <5 27.5 28.8 29.9 30.8 31.6 32.2
Heart <15 32 34.4 36.6 38.5 40.3 41.9
Spinal cord 1 <0.25 22.5 24.1 25.4 26.7 27.7 28.7
Spinal cord 2 <0.5 13.5 14.3 15.0 15.6 16.1 16.5
Lung 1 (right & left) 1500 12.5 13.2 13.8 14.3 14.8 15.2
Lung 2 (right & left) 1000 13.5 14.3 15.0 15.6 16.1 16.5
To assess the dose delivered to the organs at risk and to see if it did not exceed limits lead-
ing to toxicity, critical and maximal values from Grimm et al. (2011) and RTOG (2014) were
used which are listed in tables 5.2 and 5.3. Those are RTOG values which are used for 5*10
Gy(RBE) treatments and which were adapted for each fractionation scheme using the same
method explained above with equations 5.1 and 5.2. Two different α/β ratios were used for the
spinal cord, the heart and the lung, which are late-responding organs (with slow cellular prolif-
eration), and the esophagus, which is an early-responding organ (due to mucosa composed of
rapidly dividing cells), meaning α/β ratios of 3 and 10, respectively, as explained by Hall and
Garcia (2011).
Table 5.3.: Organ maximal point doses (MXDs) for a 5*10Gy(RBE) treatment scheme from RTOG
(2014) adapted for each fractionation scheme. Adaptation of the values was done
with an α/β ratio of 3 for the heart, the spinal cord and the lungs and 10 for the
esophagus, corresponding to late- and early-responding tissues, respectively (Hall and
Garcia, 2011).
MXD for each number of fractions [Gy(RBE)]
Organ 5 (RTOG, 2014) 6 7 8 9 10
Esophagus 105% of total planned dose (see table 5.1)
Heart 105% of total planned dose (see table 5.1)
Spinal cord 30 32.2 34.2 36.0 37.6 39.1
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Also, for some of the OARs such as the spinal cord and the lungs, 2 different dose limits were
available (see tables 5.2 and 5.3). For columns 2 and 4 to 8 of table 5.2, dose limit values
(columns 4 to 8) were compared to the dose delivered in the corresponding volume (column
2) of each organ. In RTOG (2014), the maximal point dose (see table 5.3) in the cases of the
esophagus and the heart were originally 105% of the dose prescribed to the PTV (IMRT) but it
was here applied as 105% of the planned dose in the CTV.
All simulations were performed on the weekly 4DCTs with a patient-specific planned dose
(see table 5.1). The first two brief studies aimed at finding a replanning factor and field angles
which were robust with respect to interfractional changes. In the final study, the quality of the
dose delivery to the tumor was investigated for 3D0, 4D0 and 4DN calculations as well as for
the total dose distributions. Comparison of the dose delivered to the OARs with organ dose
limits were performed using the total dose distributions only.
5.3 Results
All simulations were performed on the weekly 4DCTs with a patient-specific planned dose
(see table 5.1). The first two brief studies aimed at finding a replanning factor and field angles
which were robust with respect to interfractional changes. In the final study, the quality of the
dose delivery to the tumor was investigated for 3D0, 4D0 and 4DN calculations as well as for
the total dose distributions. Comparison of the dose delivered to the OARs with organ dose
limits were performed using the total dose distributions only.
5.3.1 Influence of the weekly range differences on target coverage
Figure 5.2 shows results obtained by comparing V95 differences between week 0 and week N
as a function of the water-equivalent tumor median range difference between both weeks. It is
possible to differentiate two behaviors corresponding to two range difference regions marked
by the two black ellipses. The first one, composed of points having range differences going
from 0 to about 6 mm, shows V95 differences comprised between 0 and 10%. The second one,
composed of points having range differences going from about 6 to 14 mm, shows V95 values
lower than 10%.
Two noticeable outliers can be observed having range differences of about 14 mm but showing
only V95 differences of 5% and 7%. They were obtained using patient 6, which has the biggest
tumor among the patients cohort. This patient showed no V95 difference below 9%, whether
the range difference was only 1 or 14 mm.
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Figure 5.2.: Target coverage difference between the weeks 0 and N as a function of water-
equivalent tumor median range difference (absolute value) between weeks 0 and
N. Vertical bars show the standard deviation of the calculations using 3 foci and 3
GW, horizontal bars show the standard deviation of the water-equivalent tumor me-
dian range difference of each of the 10 motion states, the central point being the
mean value for both of them. Two black ellipses indicate two noticeable behaviors
whether the range difference is lower or larger than about 6 mm.
5.3.2 Investigation of robust field angles
Figure 5.3 permits to observe the average water-equivalent tumor median range differences
between the planning week and the following ones (see patient-specific cases in appendix E.3.
Differences were investigated for 18 field angles spread over 180°, covering all the field direc-
tions corresponding to the side of the patient (left or right) where the tumor is located.
Looking at each patient separately, it is possible to observe field angles for which ranges be-
tween week 0 and week N are similar or where the difference is lower than 3 mm. However,
from one patient to the other, values for which the differences are low are not the same and,
except the ventral side of the patient which shows in each case average interfractional differ-
ences lower than 5 mm, no particular direction can be isolated, which would be less sensitive to
interfractional changes.
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Figure 5.3.: Average water-equivalent tumor median range differences between weeks 0 and N
for each patient and for 18 field angles covering 180° (10° apart from each other)
of the side of the patient corresponding to the tumor location. Angle values are the
same as angles displayed on figure 5.1: 90° corresponds here to the beam incidence
from the dorsal side and 270° from the ventral side of the patient, curves obtained
for tumors located on the left side were also mirrored and are displayed with dotted
lines on the right side. See appendix E.3 for weekly details for each patient.
5.3.3 Simulation of a clinical study
Figure 5.4 shows the obtained V95, V107, homogeneity and CN for 3D0, 4D0 and 4DN calcu-
lations as well as for the total treatment dose cubes. Static simulations show average values
of 95.8%, 1.5%, 8.7% and 0.59 in terms of target coverage, overdose, homogeneity and CN,
respectively. Except for one patient, all V95 values are above 93% and all V107 values below
2.5%.
Looking at 4D0 calculations permits to see that results are similar to 3D0 calculations, as illus-
trated by similar average values: 95.7%, 1.6%, 8.8% and 0.58 in terms of V95, V107, homogeneity
and CN, respectively. Extrema are also similar.
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4DN calculations show some difference compared to the two previous ones. V95 and homo-
geneity are deteriorated, as shown by their mean values which drop to 93.4% and increase to
10.%, respectively. There is also deterioration of the minimum of the V95 distribution and the
maximum of the homogeneity distribution which drops to less than 70% for 4DN calculations,
compared to about 87% in the 3D0 and 4D0 cases, and increases to about 30% for 4DN calcula-
tions, compared to 19% in the 3D0 and 4D0 cases. Distribution of CN is larger than in the 3D0
and 4D0 cases and the average value is slightly lower at 0.56.
Finally, total dose distributions yield average V95 and homogeneity of 94.3% and 8.3%. Over-
dose is lower than in the other cases, as illustrated by a mean value of 0.7% and a maximal
value also lower than in the other cases. CN shows a mean value of 0.52 and a distribution
similar to the one obtained with 4DN simulations.
Now, looking at figure 5.6, it is possible to see if dose limits in each organ at risk were re-
spected or not. Regarding dose/volume limits (see table 5.2 and middle values of figure 5.6),
dose limits are respected for all patients only for the first limit of the lung (1500cc/12.5Gy(RBE)
in RTOG (2014)). For most of the patients, dose limits concerning the spinal cord (1 and 2)
and the second lung dose limit (1000cc/13.5Gy(RBE) in RTOG (2014)) are respected but, for
two patients, the first spinal cord limit is exceeded by about 3 Gy(RBE) and 16 Gy(RBE) and
the second spinal cord limit by about 11.5 Gy(RBE) and 24.5 Gy(RBE) and for another patient,
the second lung dose limit is exceeded by about 5 Gy(RBE). In the case of the esophagus and
for 5 patients, the dose delivered to the dose-limit corresponding volume is lower than the limit
while, for 4 patients, the dose limit is exceeded, sometimes by more than 27 Gy(RBE). Results
obtained for the heart show 3 patients for which the limit is exceeded, one showing more than
25 Gy(RBE) above the limit.
Concerning the maximal point dose, values on the right of figure 5.6 show the difference be-
tween the maximal values found in each OAR and the limits listed in table 5.3. As no maximal
OAR dose limit was found in the case of the lung, it was not possible to do any calculations.
In the cases of the esophagus and the heart, all values from the total dose distributions are be-
low the maximal dose limits, except one value in each case which is very slightly higher (0.005
Gy(RBE) for the esophagus, 0.3 Gy(RBE) for the heart). Regarding the spinal cord, most of the
maximal point dose values are also below the limit but, for 2 patients, the limit is exceeded by
1.5 Gy(RBE) and 11 Gy(RBE).
As an example of 3D0 (static simulations using the planning CT), 4D0 (4D simulations using
the planning 4DCT) and 4DN (4D simulations using the following weekly 4DCTs) simulations
and to show a resulting total treatment distribution, figure 5.5 shows dose distributions ob-
tained with patient 2.
On figure 5.6, it can be observed that the minimal total dose requirement prescribed by ICRU
(2007) (V95,ICRU = 95%) is respected (green crosses) for cases showing a target coverage above
95% for 3D0 simulations already (static simulations done using the planning CT). All cases
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Figure 5.4.: Target coverage (V95), overdose (V107), homogeneity and conformity number (CN)
obtained for 3D0, 4D0 and 4DN calculations as well as for the total treatment. The
average value (marker), the median value (horizontal bar in the box), the 25th and
75th percentile and the total range of all values are given. 3D0, 4D0 and Total box
and whisker plots are composed of 9 points and 4DN ones of 61 points.
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which show a V95,Total below the ICRU requirement (red crosses) also show a V95 around or be-
low 95% for 3D0 simulations. Moreover, even though most of the OAR dose limits from RTOG
(2014) are respected in the case of patients showing a V95,Total above 95%, the dose delivered
to the esophagus and the heart exceeds the limits for two and one of them, respectively, despite
the organ constraints.
Figure 5.5.: Dose distributions obtained for patient 2. The 3D0 distribution was obtained with a
static calculation using the first weekly 4DCT (week 0), the 4D0 and the 4DN distri-
butions were obtained with 4D calculations using week 0 and week 4 of patient 2,
respectively, and the “Total” distribution was obtained by adding all the weekly de-
formed dose distributions and represents the total dose delivered during the treat-
ment. The pink contour is the CTV, the esophagus and the spinal cord are visible on
the total dose distribution.
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5.4 Discussion
5.4.1 Influence of the range differences on target coverage
Target coverage differences between weeks 0 and N showed two different behaviors corre-
sponding to range difference values lower or higher than about 6 mm, as shown on figure 5.2.
So it means that, just by analyzing a new weekly 4DCT, it would be possible to calculate the
median range of the tumor, then compute the difference with the range of the tumor on the
planning CT and have an estimation of the resulting target coverage. Obtaining less than 6 mm
as range difference would mean that the target coverage is not likely to be reduced by more
than 10%, while, by obtaining a value higher than 6 mm, one may risk to obtain severely deteri-
orated target coverage. Then, it could be decided to set a 6 mm range difference threshold as a
replanning factor, so that if the range difference would be larger than 6mm, one would not risk
to obtain a target coverage approximately 10% lower than the one obtained on the first week.
However, this would only be optimal for single field calculations for a very low amount of
fractions. Indeed, by using more fields, if one field had more than a 6 mm range difference,
it would be balanced by the two other ones and it would actually affect only one third of the
planned dose, which would then be 10% lower than expected. Thus the total dose delivered per
fraction would actually be only one 30th lower. Also if several fractions are used for the treat-
ment, this already small negative effect would be counterbalanced again by the fractionation
principle.
Therefore, the idea of a replanning factor based on interfractional range changes is not op-
timal when a multiple fields plan is used in a treatment composed of several fractions. This is
why it was decided not to use one in this study.
5.4.2 Investigation of robust field angles
Results showed that, apart from the ventral side of the patient, no particular field angle could
be isolated, which is more robust to interfractional changes than others for all patients. Conse-
quently, that field angles have to be chosen specifically for each patient.
Now, even though each patient shows optimal angles (see appendix E.3) with almost no range
differences between the planning week and the following ones, it would not have been realistic
to choose field angles according to a graph showing range differences from week 0 to N. Indeed,
the treatment plan is generated using the first 4DCT, so that, at that time, no information about
the following weeks is available. Moreover, the optimal angles shown on the weekly graphs of
appendix E.3 may not be the safest solutions regarding the organs at risk. Looking at the beam
incidence for those angles, it crosses some critical structures such as the heart or, due to range
uncertainties caused by intrafractional motion and interfractional changes, may be responsible
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for dose delivery to organs located in the vicinity of the tumor.
Also, using more fields can logically permit to divide the dose delivery by only delivering a
fraction of the planned dose for each chosen field direction but the choice of field angles has to
be done carefully, or the following negative effect might be observed: it is indeed possible that
one field angle yielding good results for one week may be responsible for huge dose delivery
errors for a following fraction if the patient’s anatomy changes or if there is any misplacement.
Thus, using more fields permits to distribute the dose over a number of entrance channels but at
the same time increases the volume in the vicinity of the tumor which might be affected by dose
delivery errors due to range changes. This could be the cause of unexpected OAR irradiation
leading to toxicity.
Therefore, field angles listed in table 5.1 were chosen based on the first weekly 4DCT also
used to generate the treatment plan so that, for each direction, the beam would avoid organs at
risk (or minimize the volume of organs) directly on its path or distal of the tumor in the same
direction. For each patient, the three field directions were also set so that their overlap was
minimal in order to avoid high dose in the surrounding tissue and organs.
5.4.3 Simulation of a clinical study
Results obtained in this chapter for the 3D0, 4D0 and 4DN regarding the dose delivery to the
tumor were deteriorated compared to those obtained in the previous chapter using gating even
though the same optimized parameters were used. This can be explained easily by the fact that
organ constraints were here taken into account which aimed at limiting the dose delivered to
the critical structures, in this case the esophagus and the heart. Because most of the tumors
were located at a reasonable distance from the spinal cord or because it was easy to choose
field directions which would avoid it, no constraints were used regarding this OAR. Figure 5.6
shows that, except for two patients, the spinal cord did indeed not need any particular atten-
tion. Dose distributions obtained for one of this patient are displayed on figure 5.5. Looking at
the position of the spinal cord and the esophagus relative to the total dose distribution, one can
observe that they are located within the CTV. This was not the only case showing such kind of
configuration, for which the CTV was contoured ignoring the nearby OARs. This was the case
for the esophagus for almost half of the patients and this is very well illustrated on figure 5.6,
on which it can be observed that, for a non-negligible percentage of patients (5 out of 9), a very
high dose exceeding the dose limit is delivered to this organ which is known to be particularly
sensitive to irradiation. This was due to the fact that the esophagus, or at least a part of it, was
actually located inside the CTV. Also, using 40% of the planned dose as maximal allowed dose
in the esophagus and the heart permitted, for each patient, to have a trade-off between target
and OAR dose delivery. A higher value would have deteriorated the tumor dose coverage and
lower value would have allowed more dose in the critical structures. However, as displayed on
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figure 5.6, it can be observed that OAR constraints used for the esophagus and the heart were
not effective for two of the cases showing a V95,Total above 95% (two green crosses below 0 in
the case of the heart and the green cross below 0 in the case of the esophagus), which means
the optimization process could not spare the OARs efficiently. For the case showing overdose in
the esophagus, it is due to the fact the esophagus is located deep inside the CTV, which leads
to the unefficiency of the 40% dose constraint and, for the two cases showing overdose in the
heart, the latter is not entirely surrounded by the tumor but still by a non-negligible part of it,
which causes median dose (30-40 Gy(RBE)) delivery in a large volume of the organ.
Now, regarding the OAR dose limits themselves, the chosen RTOG dose limits are normally
used for a 5*10 Gy(RBE) treatment, which corresponds to a ED2Gy(RBE) of 100 Gy(RBE) (using
equation 5.1) and which is lower than the 126 Gy(RBE) obtained from the chosen treatment
scheme from Miyamoto et al. (2003, 2007). It means that the chosen organ dose limits might
be slightly too low. However, adapting the treatment scheme used by Miyamoto et al. (2003,
2007) for a 5 fractions treatment (using equation 5.2), a dose of 11.5 Gy(RBE) is obtained for
each fraction, which is only 1.5 Gy(RBE) above the RTOG treatment example. Thus, that and
the fact Benedict et al. (2010) stated that dose limits are “mostly unvalidated” and that “while
most are based on toxicity observation and theory, there is a measure of educational guess-
ing involved as well”, the chosen organ dose limits can be considered legitimate even though
slightly overestimated in the sense that they are too strict. In the case of the heart and the
esophagus, although some maximal point doses obtained using the OAR constraint (40% of the
planned dose) were slightly higher than the maximal dose allowed by RTOG (2014), it can be
once again counterbalanced by the fact that those should be used for a 5*10 Gy(RBE)-based
treatment compared to the 9*8 Gy(RBE)-based treatment used in this study showing a higher
ED2Gy(RBE). Now, some of the organ dose results obtained in this study exceed limits by more
than 20 Gy(RBE), and having slightly higher dose limits (corresponding to the 9*8Gy(RBE)-
based treatment scheme chosen in this study) would not change the situation in those cases.
But, looking at OAR dose limits coming from other studies than RTOG (2014) in Grimm et al.
(2011), it could be observed that some of them were higher than the ones chosen here: up
to 52.5 Gy(RBE) for both the esophagus and the heart compared to the 27.5 Gy(RBE) and 32
Gy(RBE) from RTOG (2014), respectively. Assuming α/β ratios are similar, most of the cases
exceeding the dose limits from RTOG (2014) would then respect these higher ones.
With respect to target dose coverage, it can be noticed that, indeed, static simulations yield
deteriorated results compared to the ones obtained in the previous chapter. The reason has been
explained above and, even by trying different field combinations, results did not improve or im-
proved only slightly. As explained above, to avoid to deliver more dose to the OARs (by allowing
stricter dose constraints, meaning that more dose could have been delivered to the OARs), it
was decided to keep the dose constraints as they were initially set (40% of the planned dose)
because the resulting target coverage (V95) was not lower than 90% for most of the cases.
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Then, looking at 4DN calculations on figure 5.4 and 5.5, it is again obvious that interfractional
changes play a large role in fractionated treatments when they are compared to 4D0 results.
Baseline shift using 4D-CBCT, as proposed by Sonke et al. (2008), might allow compensating
for interfractional geometric organ shifts or tissue drifts as their study also showed that the tu-
mor trajectory was stable from one fraction to another, but not for the possible induced range
changes or for tumor shrinkage resulting in more dose in the surrounding normal tissue. Hui
et al. (2008) recommended using replanning to obtain satisfactory weekly dose delivery in the
case of large interfractional anatomic changes. In this chapter, although a few V95 values are
below 70%, most of the results were only slightly deteriorated compared to the 4D simulations
done using the planning 4DCT (4D0 simulations). So the conclusion of chapter 3, concerning
the capability of optimized parameters to compensate efficiently for both intrafractional motion
and interfractional changes, applies here as well, despite the fact static results were deterio-
rated. Moreover, looking at the total dose delivery, the effects of fractionation can be observed:
it permitted to counterbalance weeks for which dose delivery was unsatisfactory so that, finally,
only a few patients showed V95 lower than 90% and, in general, the “Total” dose delivery was
only slightly deteriorated compared to the results obtained from the static calculations. In ICRU
(2007), a possibility of dose constraints is to obtain V95 within a “-5% and +7% of the planned
dose” interval. This was obtained for 4 out of the 9 available patients (see detailed results for
patients 1, 3, 8 and 9 in appendix E.3) and, as displayed on figure 5.6, it can be noticed that
those patients are the same patients who showed a V95 above 95% for the 3D0 calculations.
Therefore, using gating and the optimized parameters found in chapter 3 permits to ensure a
conformal “Total” target dose coverage if the 3D0 one is itself above 95%. Nevertheless, three
other patients showed a V95 between 90 and 95% and the two last ones a V95 slightly below
90% (5 red crosses on figure 5.6) and, when looking at the 3D0 results on figure 5.6, it can
be observed that those patients show also results below or around 95%. Thus, while dividing
the dose delivery into several fractions appeared to be another way of compensating efficiently
for interfractional changes, final dose delivery of some patients did not fulfill ICRU (2007) dose
criterions. More importantly, the result of the static simulations using the planning CT already
permits to have an idea whether the total target dose delivery is going to be conformal or not.
Nevertheless, figure 5.5 illustrates quite well how difficult it is to plan knowing only the
anatomy on the planning week and using this treatment plan for all the following fractions.
For different rescanning configurations and for unique simulations (no successive weekly cal-
culations), Knopf et al. (2011) tested several field combinations but there was no particular
advantage of one compared to the others. In this study, only patient 8 could be considered as
a perfect case with a small tumor showing an average motion of 4 mm and located at a large
distance from any critical structure so that the three fields could be chosen orthogonal to each
other (see table 5.1), allowing thus reducing high dose regions in the ipsilateral lung while still
not affecting any OAR. For this patient, final total target coverage of about 100% was obtained.
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For all other patients, even though field directions were chosen carefully using the planning
4DCT to minimize the dose in the surrounding tissue and organs, the tumor was so close to
at least one of them that nothing, apart from using organ dose constraints, could be done to
avoid to cross the mentioned critical structure. Moreover, some patients, for which satisfactory
OAR irradiation was obtained on the first week, showed large interfractional changes from one
week to the other, leading to more dose delivered to the OARs than initially expected during the
following fractions.
To conclude this section, even though weekly dose delivery to the tumor was decreased due
to the proximity of OARs, using optimized parameters combined to the gating motion mitiga-
tion technique permitted to obtain satisfactory target coverage, overdose and homogeneity for
4 patients according to some of the ICRU (2007) constraints, the 5 other ones showing results
slightly below those constraints. It was also observed that patients showing satisfactory dose
target coverage for static simulations are likely to show conformal total treatement dose deliv-
ery as well. For most of the OARs, dose limits were respected but, in some cases, they were
exceeded mostly due to the fact the concerned OAR was located inside the CTV, close to it or in
the direction of one of the fields impacted by range changes caused by interfractional changes.
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6 Discussion
In this dissertation, the GSI in-house treatment planning system (TPS) was used and, for each
patient, all weekly simulations were done using a single treatment plan based on the planning
CT and generated for the whole treatment. The first goal of this study was to optimize treatment
planning parameters to obtain satisfactory target dose coverage for successive weekly fractions,
using gating as motion mitigation technique. Then, results obtained using gating and two other
motion mitigation techniques were compared to determine if target dose conformity could be
further improved. Finally, the simulation of a clinical study using treatment schemes and OAR
dose limits from clinical reports was performed and dose delivery to the target and the organs
at risk OARs was investigated. Several effects had to be compensated, such as intrafractional
motion (Seppenwoolde et al., 2002; Mori et al., 2007; Shirato et al., 2004), interfractional vari-
ability (Sonke et al., 2008; Mori et al., 2009; Britton et al., 2007) and interplay effects (Bert
et al., 2008). Intrafractional motion and interplay effects have already been widely studied
in the case of particle therapy (Bert and Durante, 2011), but interfractional variability and its
effect on dose delivery have not been estimated extensively for the entire course of a treat-
ment using particle therapy because available complete 4DCT datasets covering several weeks
of treatment are rare. In photon therapy, interfractional changes do not have the same impact as
in particle therapy, because photons are much less sensitive to changes in the radiological path
length. However, because of tumor shrinkage during the treatment, it might still be necessary to
re-optimize treatment plans to spare normal tissue (Britton et al., 2007). Some studies for pho-
ton radiotherapy have shown that interfractional variations can be up to 10 times larger than
tumor intrafractional motion (Nøttrup et al., 2007) and that some of the used motion mitiga-
tion techniques, such as abdominal compression, can actually increase interfractional changes
(Mampuya et al., 2013). All this shows that interfractional variability, combined with intrafrac-
tional motion in the case of lung tumors and motion-induced interplay, is a serious issue. This
study shows that, for unproblematic cases, it can be compensated using optimized parameters
and patient-specific entry channels.
Bert et al. (2009), Richter (2012) and Steidl (2011) investigated the impact of the beam focus
and the raster point spacing on the delivered dose for irradiation of moving tumors in treatment
planning studies and in experiments. Bert et al. (2009) concluded that increasing the overlap
between the pencil beams, obtained either by increasing the beam focus or by decreasing the
raster point spacing, permitted to obtain improved dose homogeneity. Richter (2012) and Steidl
(2011) both confirmed that the use of a large focus could to some extent compensate for de-
terioration of target coverage and homogeneity caused by intrafractional motion and interplay
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effects. The same impact of the focus on dose delivery was observed here. But while those pre-
vious studies concentrated on intrafractional motion and single field treatments only, this work
also has investigated the impact of interfractional variability applying an optimized treatment
plan to a number of of 4DCT datasets each corresponding to one treatment fraction. While
a larger focus can improve dose coverage in the presence of intrafractional motion and inter-
play effects, no additional benefit has been found with respect to mitigation of interfractional
changes. The reason for this is that the observed interfractional motion was mainly governed
by large geometric and range changes leading to under dose in the tumor and dose deposition
in normal tissues. Mitigation of interfractional changes could be more efficiently achieved by
using ITV-PTV margins which compensate for organ shifts or tissue drifts and range changes by
extending the irradiated volume. So, not only do the margins, combined to a mitigation tech-
nique such as gating or rescanning, permit to compensate for intrafractional motion (Albertini
et al., 2011; Knopf et al., 2013), but they can also drastically improve results for cases showing
large interfractional changes. Obviously, the disadvantage is that more dose is delivered to the
surrounding normal tissue. Now, in this work, it was also shown that multiple fields can be used
to spread the delivered dose over several entry channels and avoid high dose areas around the
tumor while leading to more conformal dose delivery to the tumor, in agreement with Knopf
et al. (2011). But, despite the use of multiple treatment fields, using ITV-PTV margins can still
lead to doses exceeding organ dose limits, as described in chapter 5 and further discussed later
in this chapter.
Considering the influence of the gating window (GW), it could be observed that the GW had
a larger influence on dose delivery using the single ITV (SITV) configuration described in ap-
pendix C, 4D simulations showing the largest V95 for the shortest GW and smallest V95 for the
longest GW. Using the appropriate ITV (AITV) configuration (also described in C), the longest
GW yielded better results and the shortest GW worse results, and it resulted in similar V95 for
the 3 GWs (see appendix C). Deciding to use the SITV configuration yielded better results using
the shortest GW, due to the fact that generating a treatment plan using 5 motion states and
delivering the 4D gating plan on only 3 motion states already formed an additional margin.
This had the same impact as ITV-PTV margins, which compensates more efficiently for inter-
fractional motion but also leads to a larger irradiated volume of normal tissue, as previously
explained. However, in spite of the larger impact of the GW for the SITV configuration, the GW
still showed a smaller influence on dose delivery than the width of the focus. This demonstrates
again that using a large focus is one of the key elements to obtain better target coverage and
better homogeneity.
Then, although gating yielded satisfactory results in terms of target coverage and homogene-
ity, a comparison with rescanning and regating processes ignoring interplay effects referred to
as perfect rescanning (PRSC) and perfect regating (PRGT) (both described in chapter 4), re-
spectively, was performed. By again using only one treatment plan, results showed that the
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three techniques yielded similar results for the dose to the tumor and the OAR. The results
obtained using techniques taking into account and ignoring interplay effects were similar, due
the fact that the intrafractional tumor motion amplitude was smaller than 5 mm for 6 out of
the 9 available patients. This lead to think that those effects, even though they can themselves
be the source of dose conformity deterioration (Bert et al., 2008), have a minor impact on dose
delivery compared to interfractional variability. The latter is indeed responsible for severe dose
delivery errors, due to the high range sensibility of ions. And as shown by Nøttrup et al. (2007),
its amplitude is also potentially much larger than the one of intrafractional motion.
Furukawa et al. (2007, 2010) at NIRS and Seco et al. (2009) at MGH have implemented
techniques combining gating and rescanning called phase-control rescanning (PCR) and breath-
sampling rescanning (BSR). Using BSR, Seco et al. (2009) showed that it is possible to obtain
minimal dose delivery errors within a short treatment time. Since fractionation and multiple
irradiations of the target permit to reduce interplay effects (Phillips et al., 1992) and since the
principle of gating is to deliver treatment during the most stable phase of the tumor motion,
combining these two techniques is potentially one of the most promising motion management
solutions available nowadays to treat moving tumors using scanned ion beam therapy. Mori
et al. (2013a,b) obtained similarly results using PCR. It is important to note that the studies us-
ing both PCR and BSR have taken into account the full temporal structure of the beam delivery,
therefore modeling the interplay effect. However, in the study presented in this work, PRGT and
rescanning both neglect the interplay effect and try to approximate the result of PCR and BSR
by a priori distributing dose contributions equally over all motion states. However, in the pre-
sented study PRGT did not show an improvement compared to gating. The differences between
this study and the study from Seco et al. (2009) can be explained by the fact that in this work
interfractional changes and intrafractional motion were considered for most of the 4D simula-
tions (simulations using weekly 4DCTs following the planning week), Seco et al. (2009) tested
BSR using simulations considering intrafractional motion only. Furthermore they performed
single field calculations with a 5 mm beam spot for a simple parallelepiped-shaped target, i.e.
a very simplified geometry with no surrounding structures. While their results demonstrate the
feasibility of the technique in a simplified setup, the robustness of this technique with respect to
interfractional anatomy changes has not been demonstrated yet.
To perform the final study in the last chapter, OAR dose constraints were used, which were
taken from RTOG (2014). Grimm et al. (2011) presented a large overview of the OAR dose
constraints currently available in the literature and used in IMRT treatments. Depending on
the source, these constraints are very variable and at least some of them are unvalidated, as
described by Benedict et al. (2010). In general, higher constraints could be found for a larger
number of fractions. The patient-specific fractionation schemes used in chapter 5 were derived
from a treatment scheme described in Miyamoto et al. (2003, 2007) but no OAR constraints
were associated with the protocols reported in these clinical reports and the dose delivered to
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the OARs was only investigated through early and late effects follow-ups. Even though Grimm
et al. (2011) assembled a large amount of data from different studies, the data was available for
IMRT treatments only using 6 or less fractions. Dose limits from RTOG (2014) were adapted to
each fractionation scheme but there is still some uncertainty in the OAR constraints used in this
work. The general tendencies observed here with respect to OAR exposure and dose conformity,
however, can be expected to be independent of the precise OAR limits used.
As the previously discussed organ constraints were used in the framework of a simulated
clinical study, using optimized parameters previously presented permitted to obtain satisfac-
tory target coverage and OAR sparing (except two cases showing overdose in the heart and the
esophagus) for four patients according to target dose constraints from ICRU (2007), while the
five other cases showed some slight underdosage in the tumor and exceeded OAR dose limits.
This emphasizes the difficulty of using only one treatment plan prior to the entire course of the
treatment in the case of patients showing large intrafractional motion sometimes combined to
interfractional changes and a tumor located in the vicinity of OARs. The aspect of replanning
has been discussed in chapter 5. Hui et al. (2008) recommend using adaptive replanning for
cases showing large interfractional anatomy changes. But in this study, due the use of several
fields which permit to distribute the dose delivery over several directions and which therefore
reduce the potential dose delivery errors, it was assumed that computing a new treatment plan
would not result in a large improvement. It was indeed observed that interfractional variability
did not impact all three field directions, but only one in general. Thus, using replanning would
only improve the situation for the concerned field direction and for only one fraction, meaning
a target coverage maximal improvement of one third of the weekly planned dose and, hence,
only a small fraction of the total planned dose. Also, because of fractionation, one weekly un-
satisfactory dose delivery can be counterbalanced by the other ones. So, unproblematic cases
showing small motion, a tumor located distant from any critical structure or, on the contrary,
an OAR located deep within the CTV (leading to the unefficiency of organ dose constraints)
permitted to obtain good results with V95 above 95% (even 100% in one case). But, for some
other patients with complex anatomy and tumor location, V95 below 90% and exceeded OAR
dose limits could have either questioned the choice of treating the patient using scanned ion
beam therapy or possibly lead to replanning to avoid too much overdose in the OARs during the
treatment.
Field angle choices could obviously be improved on an individual basis by experienced physi-
cians or by implementing an optimization algorithm which would aim at generating a treatment
plan using fields minimizing the dose delivered to the OARs and maximizing the tumor dose de-
livery. Besides, the number of fields may also be optimzed: some cases in this study showed
satisfactory target coverage (see chapter 3) and homogeneity using only two fields. Two op-
timized entrance channels might then be capable of yielding good treatment delivery while
reducing the volume surrounding the tumor in which dose is delivered. Knopf et al. (2011)
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tested several field configurations to irradiate liver tumors (the liver being located just below
the lungs and the diaphragm) but no optimal direction was found. Here, only the ventral side
of the patient showed average interfractional range changes below 5 mm for all patients. Ac-
cording to the influence of interfractional range changes on target coverage described in chapter
5, this would lead to an estimated maximal 10% decrease in V95 for single field calculations.
But using several fields would reduce this value, as explained above, making the anteropos-
terior (AP) direction a potential good field choice. However, the anatomy of the patient and
the tumor location also has to be taken into account, meaning that an OAR could actually be
present on the path of the beam consequently invalidating the previous choice. Once again, this
demonstrates the complexity of treatment planning, because a parameter set to optimize to a
specific criterion might be the cause of deterioration of another criterion.
Finally, as briefly mentioned above, one of the advantages of BSR (Seco et al., 2009) is its
capability to deliver conformal dose in a very short time of a few minutes. Treatment duration
is indeed an element that should be considered in the search for an optimal dose delivery. For
multiple reasons, patients cannot stay a long time on the couch and it is better to deliver the
treatment as fast as possible. Indeed, even though the patient is partly immobilized, a short
treatment time reduces the probability of anatomic changes or small patient motion occurring
during beam delivery. One purpose of this study was to test the feasibility of using only one
treatment plan for the entire course of the treatment instead of using a replanning strategy.
Being able to avoid replanning will keep the global treatment time low. Even though GPU-based
treatment planning has been investigated and permits to decrease plan optimization times by a
factor of 20 to 40 for IMRT, as shown by Men et al. (2009), it is still far from being clinically
used, because the GPU-based treatment plans need firstly to be compared with regular treatment
plans for validation and also because it requires large hardware and software upgrades.
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7 Conclusion
In this dissertation, using the GSI in-house 4D treatment planning system TRiP4D and a co-
hort of patient time-resolved computed tomography (4DCT) datasets for lung tumor patients,
4D gating simulations using scanned ion beam therapy have been performed.
In the first study (chapter 3), which aimed at finding optimized treatment planning param-
eters in order to compensate for dose delivery deterioration caused by intrafractional tumor
motion, that is interplay effects and interfractional variability, it was found that the use of a
large focus (15 mm, FWHM), a short gating window (11.9% of the motion amplitude), addi-
tional ITV-PTV margins (3mm isotropic + 3%+3mm range margins) and 3 fields yielded the
best results in terms of target dose coverage (average V95 = 96.9%). Using this configuration,
intrafractional motion was efficiently compensated. However, due to the additional margins,
more dose was delivered to the surrounding normal tissue.
In chapter 4, results obtained using perfect rescanning (PRSC) and perfect regating (PRGT)
(both ignoring interplay) were compared to those obtained using gating but did not yield an im-
provement. Results in terms of target coverage were indeed very close: 97% for gating, 96.2%
for PRSC and 98% for PRGT, meaning that interplay effects did not have a large impact on dose
delivery and that these effects and intrafractional tumor motion were already efficiently com-
pensated using gating. The remaining influence of interfractional organ motion on the delivered
dose was similar for all three studied techniques. Thus, using gating, the final study aimed at
estimating the potential influence of interfractional motion on the total dose delivered to the
tumor and the organs at risk (OARs) during the treatment and at determining if it could be
mitigated.
Two first brief studies in chapter 5 showed that a replanning factor would not yield an addi-
tional advantage due to the use of multiple fields which spread the dose over several entrance
channels and that, apart from the ventral side of the patient, no robust field direction could be
isolated. Finally, the simulation of a clinical treatment course using gating and the optimized
parameters previously found in chapter 3 permitted to demonstrate that the total V95 obtained
over the entire course of the treatment was similar to the one obtained for the planning CT,
meaning that interfractional variability was efficiently compensated. Therefore, for 4 patients
out of the 9 available, which showed a V95 above for the planning CT, it was possible to obtain
V95 > 95% as well for the total target dose coverage. For the 5 other cases, modifying slightly the
contours or reducing the planned dose should also lead to an acceptable clinical plan that could
effectively be delivered over the course of the treatment in spite of interfractional changes.
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A Comparison of different rigid registration
methods for 4DCT alignment
A.1 Introduction
Using Plastimatch (Shackleford et al., 2010), soft tissue rigid registration is the method which
was used in this study to align weekly 4DCTs so that the same coordinates could be used from
one week or fraction to another. It showed successful results and permitted to yield aligned
CTs in most of the cases. However, it seemed to partly fail for one weekly 4DCT, causing
misalignments leading to non-conformal dose delivery. The idea was then to align CTs using
only the bony anatomy and not the complete range of Hounsfield units present in the datacube,
and to investigate the impact on the obtained results in terms of target coverage, overdosage,
homogeneity and conformity number.
A.2 Materials and methods
A.2.1 Patient data
4DCT datasets from 2 NSCLC lung tumor patients from MDACC (Britton et al., 2007) were
used to investigate the difference between soft tissue and bony anatomy registration. Patients 3
and 9 described in chapter 3, composed of 9 and 6 weekly 4DCTs and having an average tumor
motion of 10.1 mm and 23.5 mm, respectively, were chosen among the available patients. Week
9 of patient 3 is the week for which soft tissue rigid registration failed to create vector fields
able to align correctly the CTs.
A.2.2 Soft tissue rigid registration as CT alignment method
The method used to align weekly 4DCTs in this thesis is described in the blue steps on fig-
ure A.1. It is based on soft tissue rigid registration, meaning the whole CTs undergo rigid
registration.
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Figure A.1.: Description of the two different rigid registrations used to align weekly CTs. Blue
steps are soft tissue rigid registration specific, green steps are bony anatomy rigid
registration specific, striped steps are common to the two methods.
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Figure A.2.: CTs before (images on the left) and after (images on the right) Hounsfield units
based thresholding. Antero-posterior (AP) view is displayed on a and b, superior-
inferior (SI) view is displayed on c and d and left-right (LR) view is displayed on e
and f.
Reference phases of each weekly 4DCT are thus used to create vector fields between week 0
and the following weeks. Using those, all phases of each weekly 4DCT can be aligned rigidly
to the corresponding ones of the first week. Afterwards, using the reference phase of the new
aligned CTs, it is possible to perform non-rigid registration to obtain a new deformable vector
field which is used to propagate the organ contour from one week to another. Deformable
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registration between reference phase and the 9 other phases of each 4DCT is then done to
create the deformable vector fields necessary to the 4D treatment calculations.
A.2.3 Bony anatomy rigid registration as CT alignment method
Investigated as comparison here, rigid registration using only the bony anatomy is presented
in the green steps of figure A.1. The principle is similar, except only the bony anatomy present in
the CT is used instead of the whole datacube. It means that, before vector fields are created, low
and high Hounsfield units’ (HU) thresholds are used on each reference phase CT and only values
between 100 and 1000 are selected. An example of a resulting CT can be seen on figure A.2.
Only then, using this time the “bony” CT, vector fields are generated using rigid registration
between reference phases of week 0 and the following weekly 4DCTs. Finally, the obtained
vector fields are used to align all the phases of the complete 4DCTs (entire datacubes). The
following (organ contour propagation and non-rigid vector fields between each 4DCT phase) is
similar to the previous paragraph.
A.2.4 Data analysis
The dose distribution of each week was obtained by accumulating the dose delivered to each
motion state on the reference phase of the 4DCT using state-to-state non-rigid vector fields. V95,
V107, homogeneity and CN were analyzed to investigate the differences between the two types
of registration. A Wilcoxon signed-rank test (W ) was performed using a level of significance of
0.05 to estimate the difference between two sets of datapoints. As the samples contain more
than 10 values, the p-value (p) was computed using the obtained z-score (z).
A.3 Results
V95, V107, homogeneity and CN are quite similar, no matter whether soft tissue or bony
anatomy rigid registration was used. Some significant trends (p < 0.05) can be pointed
out, such as better V95 and CN and higher V107 when bony anatomy registration is used, but
the amplitude of the changes are small (see figure A.3). Apart from all the similar weeks, for
weeks 4 and 9, homogeneity was not computable (D95 level was not reached) for simulations
done using CTs aligned with bony anatomy rigid registration and soft tissue rigid registration,
respectively.
Also, weeks 9 and 12 show a large difference between the two cases, with a mean V95 which
is almost 17% higher in the case of bony anatomy registration for the first example and a mean
homogeneity and a mean V95 which are 32% and 9% worse, respectively, also in the case of
bony anatomy rigid registration for the second one.
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Figure A.3.: Results obtained using soft tissue (red) and bony anatomy (blue) rigid registration
as weekly 4DCT alignment method. Each bar shows 4D simulations which were
performed using the 9 combinations possible using 3 different beam foci (6, 10 and
15 mm, FWHM) and 3 different GWs (11.9, 30 and 50% of the motion amplitude) for
each week of patients 3 (weeks 1 to 9) and 9 (weeks 10 to 15). Bars represent the
distribution from minimum to maximum and the markers correspond to the mean
values.
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A.4 Discussion and conclusion
Using bony anatomy rigid registration to align weekly 4DCTs did not show large differences
with results obtained using soft tissue rigid registration in general, as shown by the very low
difference between V95, V107, homogeneity and CN. It did permit to improve significantly the
results in terms of V95 for week 9 of patient 3, which was the week that soft tissue rigid regis-
tration had failed to align correctly. However, looking at the patient 3 and its third week, the
opposite effect could be observed. It means bony anatomy rigid registration could maybe be
performed in the case soft tissue rigid registration fails to align CTs, but there is yet no reason
to replace it completely and use only the bony anatomy in the first place. This is why this com-
parison has been done with only two patients and why aligned 4DCTs obtained using soft tissue
rigid registration have been used in this thesis.
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B Lung contours extraction from 4DCT
datasets
B.1 Introduction
Because the goal of this thesis is to obtain conformal dose delivery to lung moving tumors
while respecting the organ at risk (OAR) dose limits, it was necessary to have the important
OAR contours to observe their irradiation during treatment. However, although contours of the
heart, the spinal cord or the esophagus were provided with the 4DCT datasets, lung contours
were not. Thus, an algorithm had to be implemented in order to extract them from the reference
phase of each 4DCT.
B.2 Materials and methods
B.2.1 Patient data
A total of 70 weekly 4DCTs from 9 NSCLC lung tumor patients from MDACC (Britton et al.,
2007) were used in this thesis, as described in chapter 3. For each weekly 4DCT, although
different tumor and organ contours such as the clinical target volume (CTV) or the heart, re-
spectively, were provided by physicians, the lung contours had to be extracted to investigate the
dose received in different treatment configurations.
B.2.2 Lung contour extraction algorithm
Even though the aim was to implement a common algorithm to be used with all 4DCTs,
some patient-specific parameters had to be used. For one patient, one additional step had to
be implemented as well. First step consisted in simple low and high Hounsfield units (HU)
threshold combined to volumetric selection (step 1 on Figure B.1). Table B.1 shows patient-
specific threshold values that were used as low and high thresholds.
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Table B.1.: Thresholds used to isolate lung tissue [HU] in the first step and minimal volumes
[voxels] used to identify lungs in the fifth step.
Patient
Lower Higher Minimal
threshold threshold volume
1 -900 -650 30,000
2 -850 -400 30,000
3 -900 -600 50,000
4 -850 -400 30,000
5 -925 -500 500,000
6 -900 -500 100,000
7 -900 -500 100,000
8 -950 -700 100,000
9 -800 -450 100,000
However, even though lung tissue voxels were isolated, some parts of the couch as well
as some other organ tissue whose values were comprised in the thresholding window were
selected as well, meaning an additional step had to be performed. Volumetric selection was
then implemented by using a 2D-Gaussian (equation B.1) on each CT-slice and selecting voxels
comprised in the area where values were higher than 5.5.
2DG = 10× exp

−(x − x0)
2
2σx
− (y − y0)
2
2σy

(B.1)
where x0 and y0 are the coordinates of the center of the CT slice and σx=x0⁄2 and σy=y0⁄2.
After those two first steps, the original CT cube was transformed into a binary cube containing
lung tissue, but also other residual structures (limited due to the volumetric selection, see result
of step 1 on figure B.1).
Combining dilating and eroding then permitted to remove the air cavities in the lung such
as bronchioles and alveoli. The principle of dilating is, if a voxel binary value is equal to 0
(representing air), to set it to 1 if the distance to the nearest lung voxel is less than a given
length (3 mm in this study). Eroding is the opposite: if a lung voxel is closer than a given length
(3 mm again) to an air voxel, it is then set to 0. The dilating/eroding combination was done
two times in a row (step 2 on figure B.1), followed by two other successive eroding steps (step
3 on figure B.1).
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Figure B.1.: Description of the two different rigid registrations used to align weekly CTs. Blue
steps are soft tissue rigid registration specific, green steps are bony anatomy rigid
registration specific, striped steps are common to the two methods.
B.2. Materials and methods 105
Those aimed at reducing the lung volumes enough (especially in the region located in the
front of the chest where the two lungs almost touch each other) so that the two lungs can be
separated in order to yield two different contours files containing the left and the right lung. It
also permitted to remove the residual undesired structures such as the couch (see result of step
3 on figure B.1). That is why, for all patients but patient 3 (particular case described later in this
section), lung separation and isolation was done automatically using those two eroding steps
and size thresholds (see Table B.1 and step 4 on figure B.1) to ignore the undesired structures
remaining in the binary cube, if the two eroding steps did not make them disappear, resulting
in two binary files containing the left lung for one and the right lung for the other.
Figure B.2.: Diagram of the lungs representing the different lobes and segments, from
Wikipedia. In the right lung (here on the left), the apical (AP), the posterior (P)
and the anterior (AN) segments compose the superior lobe, the lateral (L) and the
medial (M) segments the middle lobe and the superior (S), the medial-basal (MB),
the anterior-basal (AB), the lateral-basal (LB) and the posterior-basal (PB) segments
the inferior lobe. In the left lung (here on the right), the apico-posterior (APP)
and the anterior (AN) segments compose the superior lobe, the inferior-lingular
(IL) and superior-lingular (SL) segments the middle lobe and the superior (S), the
anteromedial-basal (AMB), the lateral-basal (LB) and the posterior-basal (PB) seg-
ments the inferior lobe.
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In each of the two obtained binary cubes, the next step consisted in filling missing voxels
(step 5 on figure B.1). For each voxel whose value was 0 in the binary cubes, the same voxel
in the original CT was analyzed and if its value was in the same HU window as for step 1 (or
slightly different), the voxel was set to 1 in the binary cube. All voxels in the same CT slice in
a 3 by 3 neighborhood underwent the same tests, and if one of those corresponded to the same
conditions, its neighborhood was also checked and so on. This was iterated slice by slice until
all voxels were analyzed. Due to the carina and its HU which were similar to the lungs, this was
not done in 3 dimensions because it would have linked the two lungs back together through
the structure of the carina. To remove the last “air” values in each lung (“0” values), dilating
and eroding were performed one time each (step 6 on figure B.1). Finally, the planning target
volume (PTV) was subtracted to the corresponding lung file and each one of the two lung binary
files was transformed into contour files using TRiP (step 7 on figure B.1). The final result can
be observed on figure B.1.
As previously mentioned, one additional step had to be implemented for patient 3 in order
to separate the two lungs. Because, for this patient, the lungs were very close on the ventral
side, the dilating/eroding steps (step 2 on figure B.1) linked the two lungs together so that the
following step (eroding two times: step 3 on figure B.1), even when performed 3 times, did not
manage to yield the two separated lungs. It means that the two lungs were linked and that they
were present on both left lung and right lung binary files, even after the normally successful
separation step (step 4 of figure B.1). Thus a new step was placed directly after step 1 of figure
B.1 and consisted in finding the minimal value of the projection of a CT slice on the horizontal
axis. The aim was to find the location where the lungs almost touch each other in the front of
the chest so that the coordinates can be used later (before step 7 of figure B.1) to separate them.
B.3 Results & conclusion
For all patients, the obtained contours were conformal to the shape of the lungs when directly
compared to the corresponding CTs. However, due the choice of filling missing voxels (step 5
on figure B.1) only in 2 dimensions, some extreme parts of the lungs such as the posterior-basal
segment of the inferior lobes or the extreme top part of the apical segment of the superior lobes
(see figure B.2) were ignored. But performing the same in 3 dimensions, which would yield
the whole lungs without missing parts, linked them back together through the carina due to
its similar HU values. That is why the following trade-off was chosen, aiming at keeping lungs
separated (using only 2D filling of missing voxels) but missing at the end small parts of the
lungs, representing a negligible volume compared to the total size of the organ. The additional
step implemented specifically for patient 3 was also quite successful and managed to yield quite
precisely the separation point of the two lungs, as displayed on figure B.3.
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Figure B.3.: Example of lung contours (in yellow) obtained for patient 3.
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C Feasibility of using a single ITV for
different gating windows
C.1 Introduction
Using a 4D treatment planning system (4DTPS) from GSI, TRiP4D (Richter et al., 2013),
and range adapted-ITV margins (Graeff et al., 2012) permits to investigate the effect of several
parameters on weekly 4D treatment simulations. In this dissertation, gating (Ohara et al., 1989;
Minohara et al., 2000) was one of the investigated motion mitigation methods. The aim of this
brief study is to investigate whether using a single ITV or corresponding ITVs for three different
gating windows leads to significant changes on dose distribution.
C.2 Materials and methods
C.2.1 Patient data
4DCT datasets from 2 NSCLC lung tumor patients from MDACC (Britton et al., 2007) were
used to investigate the difference between dose distributions obtained a single ITV or GW-
corresponding ITVs for different gating windows. Patients 8 and 9 from chapter 3, composed of
8 and 6 weekly 4DCTs and having an average tumor motion of 4 mm and 23.5 mm, respectively,
were chosen among the available patients, representing a small motion and a large motion
example.
C.2.2 Treatment planning
Treatment planning specifications were the same than the ones described in chapter 3 of this
study except for the ITV. Figure C.1 represents the two options that were compared: appropriate
ITV (AITV), represented by cases a, b and c for GW-corresponding ITVs, and single ITV (SITV),
represented by case d for one single ITV combined to each GW. GW 30% simulations were
identical for the two configurations because the ITV was the same (phases 3-7 in each case).
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Figure C.1.: Different cases compared. Cases a, b and c were calculated using the corresponding
ITV for each GW (AITV), case d shows the other possibility to perform all GW-specific
simulations using only one ITV (SITV).
C.2.3 Data analysis
The dose distribution of each week was obtained by accumulating the dose delivered to each
motion state on the reference phase of the 4DCT using state-to-state non-rigid vector fields. V95,
V107, homogeneity and CN were used to compare the results. In each case, a Wilcoxon signed-
rank test (W ) was performed using a level of significance of 0.05 to estimate the difference
between two sets of datapoints. In the case of samples containing more than 10 values, the
p-value (p) was computed using the obtained z-score (z).
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C.3 Results
In the case of the median GW (30%), no change was logically observed because the ITV is
identical for the two cases.
Then, looking at each patient separately and beginning with patient 8 (small motion), it is pos-
sible to see that for most of the cases, using an appropriate ITV yields better V95 for the long GW
with foci 6 and 15 and lower V95 for the short GW with foci 6 mm and 10 mm (W >Wcri t ical).
V107 is only significantly (W > Wcri t ical) affected in the cases 10/11.9 and 15/50 of figure C.2
with lower values in the AITV case, even though the changes are slight. Homogeneity is also only
slightly affected, because only cases 6/50 and 10/50 show better homogeneity (W >Wcri t ical).
Finally, using the AITV configuration, CN is lower with the largest focus and higher with the
smallest focus (W > Wcri t ical). Now, whether it is for V95, V107, homogeneity or CN, the differ-
ences between the two configurations are not large.
Patient 9 (large motion) shows more important differences but similar trends. Thus, using
the AITV configuration permits to obtain better V95 with the longest GW but lower V95 with the
shortest one, no matter which focus is used (W >Wcri t ical). Regarding V107, no particular trend
can be isolated except for the cases 6/11.9 and 10/50 with lower and higher V107, respectively,
when the AITV configuration was used. Using the AITV configuration permits to improve ho-
mogeneity for the longest GW and all foci but deteriorates it in the case 15/11.9 of figure C.2
(W > Wcri t ical). Finally CN is improved in the AITV case using the longest GW and foci 6 mm
and 10 mm (W >Wcri t ical).
Finally, looking at the significance of the difference between the two configurations and using
both patients for the comparison, the same trends can be observed once more. V95 is better when
the AITV configuration is used with the longest GW while it is lower when the AITV configura-
tion is used with the shortest GW, no matter which focus is used (p < 0.05). V107 is only slightly
but significantly better in the cases 6/11.9 and 10/11.9 for the AITV configuration (p < 0.05).
Using the latter yields better homogeneity in the case of the longest GW but significantly lower
homogeneity is only obtained with a focus of 6 mm in the case of the shortest GW (p < 0.05).
Finally CN did not show any significant trend (z > zcri t ical in each case).
Dose distributions of figure C.3 display comparisons between the two configurations for the
two concerned GW (11.9 and 50%).
C.4 Discussion & conclusion
Looking at the comparison of the two configurations using both patients, it seemed that trends
were more important for V95 for which, no matter which focus was used, better values were
obtained in the case of the longest GW and lower values in the case of the shortest GW using
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the appropriate ITV. For V107, homogeneity and CN, some trends could also be observed, but
not applied to each focus.
Figure C.2.: Comparison of results for patient 8 and 9 using one single ITV (SITV, blue) and
GW-corresponding ITVs (AITV, red). Each bar is composed of 8 and 6 points for
patients 8 and 9, respectively, and the comparison is displayed for each focus/GW
combination.
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Obtaining better target coverage for the long GW by using appropriate ITVs was expected
since the treatment plan is applied to a too large volume in the SITV case, which means dose
will not be delivered to the extreme phases (2 and 8 for this GW) of the 4DCT. And it is the
opposite for the short GW, as if additional margins were already used to extend the target, thus
improving motion compensation.
Moreover and quite logically, the larger the motion is, the more important the differences are.
As most of the patients of this thesis show tumor motion lower than 20 mm, it can be expected
that the impact on V95 of using the SITV configuration will be in between the two examples
shown in this brief study. Also, as using an appropriate ITV has only a small impact on V107,
homogeneity and CN, and as it permits to obtain better results using a short GW, it was decided
to use the SITV configuration in this thesis.
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Figure C.3.: Comparison of dose distributions obtained using the AITV and SITV configurations.
Columns 1 and 3 show AITV configurations for the GW 11.9% and 50%, respectively,
while column two shows the SITV configuration.
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D Impact of the TRiP contour extension
value on overdose
D.1 Introduction
In chapter 3, gating simulations showed increased overdose when more fields were used. A
modification of a TRiP-specific treatment planning parameter, known as “contour extension”
and which will be described in this appendix, was thus performed to see if using a higher value,
as recommended by Weber (1996) to run realistic simulations, would permit to obtain lower
overdose.
D.2 Materials and methods
D.2.1 Patient data
Six patients from the 9 listed in chapter 3 were used to investigate the effect of the contour
extension on overdose: patients 1, 2, 3, 7, 8 and 9, meaning that a total of 44 weekly 4DCTs
were used. Number of weeks for each patient, alignment and registration methods and fields
are the same as presented in chapter 3.
D.2.2 Simulations
All gating plans were simulated using the GSI 4D treatment planning system (4DTPS) TRiP4D
(Richter et al., 2013), based on TRiP98 and modified to allow 4D dose calculations. The gating
process used in this chapter is also the same as in chapter 3. One gating window (GW, 11.9%
of the amplitude), 3 different foci (6, 10 and 15 mm, FWHM), 3 fields (see chapter 3) and PTV
margins (3FPTV case of chapter 3) were used for each weekly 4DCT, representing 3 focus/GW
combinations. The motion surrogate (sine square with a unique period 3.6 seconds) and the
ITV definition (range corrected ITV composed of 5 motion state CTVs representing 25% of the
amplitude) were the same as in chapter 3. For each patient, plans were initially optimized to
this ITV computed with the first week’s CT, using one unique planned dose of 8.1 Gy(RBE).
Also, the distance between each raster position was set to 2 mm on each iso-energy slice and
the distance between two iso-energy slices was set to 3 mm water-equivalent.
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D.2.3 Contour extension
The principle of the contour extension in TRiP is explained on figure D.1. A quick comparison
was done to observe the impact of the contour extension value on overdose (V107): gating
simulations using the value used in chapter 3 (0.35) and the value recommended by Weber
(1996) (1.1, to take into account an appropriate lateral dose fall off) were compared.
Figure D.1.: Principle of the contour extension in TRiP. Artificially extending the CTV permits to
add additional raster points outside of the original CTV and to obtain satisfactory
dose coverage for the entire CTV without overdose.
D.2.4 Data analysis
The dose distribution of each week was obtained by accumulating the dose delivered to each
motion state on the reference phase of the 4DCT using state-to-state non-rigid vector fields. The
impact of the contour extension value on V107 was investigated. A Wilcoxon signed-rank test
(W ) was performed using a level of significance of 0.05 to estimate the difference between two
samples. Because samples contained more than 10 values, the p-value (p) was computed using
the obtained z-score (z).
D.3 Results
All results were simulated on the weekly 4DCTs with a planned dose of 8.1 Gy(RBE). In all
following figures the average value (marker), the median value (horizontal bar in the box), the
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25th and 75th percentile and the total range of all values are given. Details about the planned,
static dose on the first week (3D0), the 4D dose on the first week (4D0) and the 4D dose on all
following weeks (4DN) are given in chapter 3.
Figure D.2 show the influence of the contour extension value used in TRiP on overdose for
4D 3FPTV simulations (4D0 and 4DN mixed together) using three foci and one gating window,
representing 18-27 datapoints for each contour extension value and patient. Using a contour
extension value of 0.35 as in chapter 3 yielded a mean overdose of 3%. Some patients were
more affected than others, like patient 8 showing an average V107 of 8.5%, compared to patient
2 and its average V107 of 0.7%.
Figure D.2.: Impact of the contour extension value on V107. Each bar represents 4DN simulations
done using one GW (11.9% of the amplitude), three different foci, PTV margins and
3 fields, representing for each patients three times the number of available weeks
(as described in chapter 3).
Using 1.1 as contour extension value permitted to reduce overdose in each case (p < 0.05)
and to obtain a mean V107 lower than 0.1%. Patient 8, whose V107 was high, showed a large
improvement, falling down to 0.2% and patients for which V107 was already low (1, 2 and 7)
showed values almost equal to 0%.
Figure D.3 shows the difference on dose distributions between the two contour extension
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values with the example of week 6 of patient 3. Overdose (pink regions) present above the
tumor on the top image (corresponding to the low contour extension value) disappears on the
bottom image (corresponding to the appropriate contour extension value). Some overdose can
still be observed on the right of the tumor but the global overdose region is drastically reduced.
D.4 Discussion & conclusion
Results showed that using an appropriate contour extension value permitted to improve sig-
nificantly the results in terms of overdose. Using 0.35 as contour extension value (like in the
previous chapter) was not satisfactory because, in order to obtain 100% of the planned at the
edge of the CTV, the fluence of the last lateral raster point had to be increased and it resulted
in overdose. Here, choosing 1.1 as a new value permitted to take into account raster points
located outside the original CTV so that 100% of the planned dose could be delivered to the
whole CTV without overdose. The other consequence was that the lateral dose fall-off might be
slightly widened.
To conclude, the problem which appeared in chapter 3 when more fields were added, consist-
ing in overdose inside and in the vicinity of the tumor and in an undesired tail in the dose volume
histograms (DVHs), could be solved here. V107 values showed significant improvement (figure
D.2) which was also visible on dose distributions (figure D.3). Thus, it has also been shown that
using appropriate treatment settings, such as an appropriate TRiP contour extension value, is
mandatory to obtain conformal dose delivery and, in this case, very low overdose.
118 D. Impact of the TRiP contour extension value on overdose
Figure D.3.: Dose distributions obtained using a low (0.35, top) and an appropriate (1.1, bottom)
contour extension value. Overdose (pink regions) can be easily observed on the top
image and drastically reduced when the correct contour extension value is used
(bottom). The pink contour represents the CTV.
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E Detailed patient and weekly graphs
This appendix contains detailed results of all patient weekly calculations done in this disser-
tation. Section E.1 corresponds to calculations presented in chapter 3, section E.2 to chapter 4
and section E.3 to chapter 5.
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E.1 Optimization of treatment planning parameters
E.1.1 Focus and gating window (GW)
Figure E.1.: Detailed results of the impact of the gating window (GW) and the focus (F) on target
coverage V95.
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Figure E.2.: Detailed results of the impact of the gating window (GW) and the focus (F) on over-
dose V107.
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Figure E.3.: Detailed results of the impact of the gating window (GW) and the focus (F) on
homogeneity.
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Figure E.4.: Detailed results of the impact of the gating window (GW) and the focus (F) on the
conformity number (CN).
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Figure E.5.: Detailed results of the impact of the gating window (GW) and the focus (F) on the
20% dose volume V20 in the organs at risk OAR.
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Figure E.6.: Detailed results of the impact of the gating window (GW) and the focus (F) on the
maximal dose point (MXD) in the organs at risk OAR.
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E.1.2 Margins
Figure E.7.: Detailed results of the impact of different margins on target coverage V95.
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Figure E.8.: Detailed results of the impact of different margins on overdose V107.
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Figure E.9.: Detailed results of the impact of different margins on homogeneity.
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Figure E.10.: Detailed results of the impact of different margins on the conformity number (CN).
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Figure E.11.: Detailed results of the impact of different margins on the 20% dose volume V20 in
the organs at risk (OARs).
132 E. Detailed patient and weekly graphs
Figure E.12.: Detailed results of the impact of different margins on the maximal dose point
(MXD) in the organs at risk (OARs).
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E.1.3 Number of fields
Figure E.13.: Detailed results of the impact of different numbers of fields and margins on target
coverage V95.
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Figure E.14.: Detailed results of the impact of different numbers of fields and margins on over-
dose V107.
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Figure E.15.: Detailed results of the impact of different numbers of fields and margins on
homogeneity.
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Figure E.16.: Detailed results of the impact of different numbers of fields and margins on the
conformity number (CN).
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Figure E.17.: Detailed results of the impact of different numbers of fields and margins on the
20% dose volume V20 in the organs at risk (OARs).
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Figure E.18.: Detailed results of the impact of different numbers of fields and margins on the
maximal dose point (MXD) in the organs at risk (OARs).
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E.2 Comparison of different mitigation techniques
Figure E.19.: Detailed results yielded by gating, perfect rescanning (PRSC) and perfect regating
(PRGT) regarding target coverage V95.
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Figure E.20.: Detailed results yielded by gating, perfect rescanning (PRSC) and perfect regating
(PRGT) regarding overdose V107.
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Figure E.21.: Detailed results yielded by gating, perfect rescanning (PRSC) and perfect regating
(PRGT) regarding homogeneity.
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Figure E.22.: Detailed results yielded by gating, perfect rescanning (PRSC) and perfect regating
(PRGT) regarding the conformity number (CN).
E.2. Comparison of different mitigation techniques 143
Figure E.23.: Detailed results yielded by gating, perfect rescanning (PRSC) and perfect regating
(PRGT) regarding the 20% dose volume V20 in the organs at risk (OARs).
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Figure E.24.: Detailed results yielded by gating, perfect rescanning (PRSC) and perfect regating
(PRGT) regarding the maximal dose point (MXD) in the organs at risk (OARs).
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E.3 Simulation of a clinical study
E.3.1 Investigation of robust field angles
Figure E.25.: Weekly water-equivalent tumor median range differences for patient 1.
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Figure E.26.: Weekly water-equivalent tumor median range differences for patients 2 and 3.
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Figure E.27.: Weekly water-equivalent tumor median range differences for patients 4 and 5.
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Figure E.28.: Weekly water-equivalent tumor median range differences for patients 6 and 7.
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Figure E.29.: Weekly water-equivalent tumor median range differences for patients 8 and 9.
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E.3.2 Simulation of a clinical suty
Figure E.30.: Detailed results yielded by gating, perfect rescanning (PRSC) and perfect regating
(PRGT) regarding target coverage V95.
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Figure E.31.: Detailed results yielded by gating, perfect rescanning (PRSC) and perfect regating
(PRGT) regarding overdose V107.
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Figure E.32.: Detailed results yielded by gating, perfect rescanning (PRSC) and perfect regating
(PRGT) regarding homogeneity.
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Figure E.33.: Detailed results yielded by gating, perfect rescanning (PRSC) and perfect regating
(PRGT) regarding the conformity number (CN).
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